A data processing method, device, system and storage medium

Abstract

The embodiments of the present application provide a data processing method, device, system and storage medium. In the embodiments of the present application, the various medical devices involved in the data processing are aggregated through a computing device, and based on the traceability code obtained for the drugs to be used, a one-object-one-code mechanism can be adopted to achieve full traceability of data processing; moreover, the various medical devices no longer interact directly with each other, and each medical device cannot directly access the index information of the drugs to be used during the interaction with the computing device, which enables each medical device to carry out data processing work normally without leaking the index information of the drugs to be used, thereby improving the confidentiality of the data processing process, and can comprehensively, truthfully, objectively and effectively record and evaluate the data processing process.

Description

Technical Field

[0001] The present application relates to the field of data processing technology, and in particular to a data processing method, device, system and storage medium. Background Art

[0002] In recent years, my country's pharmaceutical companies have strengthened their independent R&D capabilities, and the development of new drugs has gained momentum. In new drug development, various blinded trials are necessary to ensure that neither the tester nor the testee knows which group (experimental or control) the testee belongs to during the trial. Furthermore, when analyzing the data, the analyst is also unaware of which group the data belongs to. This is intended to eliminate any subjective bias that may arise in the minds of both the experimenter and the participants.

[0003] However, traditional blinding schemes have problems such as low blind bottom security and low traceability of the authenticity and integrity of trial records, which affect the effectiveness and objective evaluation of the entire clinical trial. This is a problem that all parties involved in clinical trials (participants and regulators) are very troubled by. Summary of the Invention

[0004] Various aspects of the present application provide a data processing method, device, system, and storage medium to improve the confidentiality of the data processing process and achieve full traceability of data processing.

[0005] An embodiment of the present application provides a data processing system, comprising a computing device, and a first medical device and a second medical device communicatively connected to the computing device;

[0006] The first medical device is configured to obtain a first traceability code for the drug to be used, generate index information of the drug to be used based on the first traceability code, and provide the index information to the computing device;

[0007] The second medical device is configured to distribute the drug to be used to a user and provide mapping information between the drug to be used and the user to the computing device;

[0008] The computing device is configured to determine a second traceability code of a specific to-be-used drug associated with a specific drug user based on the mapping information and the index information.

[0009] The present application also provides a data processing method, including:

[0010] Obtaining index information of a drug to be used from a first medical device, wherein the index information includes a first traceability code of the drug to be used;

[0011] acquiring mapping information between the to-be-used drug and the user from a second medical device;

[0012] A second traceability code of a specific to-be-used drug associated with a specific drug user is determined according to the mapping information and the index information.

[0013] The present application also provides a data processing method, including:

[0014] Obtain the first traceability code for the medicines to be used;

[0015] generating index information of the drug to be used according to the first traceability code;

[0016] The index information is provided to a computing device so that the computing device can determine a second traceability code of a specific drug to be used associated with a specific user based on the index information and mapping information between the drug to be used and the user obtained from a second medical device.

[0017] The present application also provides a data processing method, including:

[0018] Obtaining information about drug users;

[0019] Obtaining from the computing device the intermediate code corresponding to the first traceability code of the drug to be used and the allocation group to which it belongs;

[0020] Allocating the intermediate code to the user based on the intermediate code corresponding to the first traceability code of the drug to be used and the allocation group to which it belongs;

[0021] The mapping information between the intermediate code and the drug user is provided to the computing device, so that the computing device decodes the intermediate code in the mapping information to determine the second traceability code of the specific drug to be used associated with the specific drug user.

[0022] The present application also provides a data processing method, including:

[0023] Sending a medication query request to a computing device, wherein the medication query request includes information of a specific medication user;

[0024] receiving a second traceability code of the specific to-be-used drug associated with the specific drug user returned by the computing device, wherein the second traceability code is determined by the computing device based on a mapping relationship between the to-be-used drug and the drug user provided by a second medical device and the first traceability code of the to-be-used drug;

[0025] The specific drug to be used is obtained according to the second traceability code and distributed to the specific drug user.

[0026] An embodiment of the present application further provides a computing device, including a memory, a processor, and a communication component;

[0027] The memory is used to store one or more computer instructions;

[0028] The processor is coupled to the memory and the communication component and is configured to execute the one or more computer instructions for:

[0029] Obtaining index information of the drug to be used from the first medical device through the communication component, wherein the index information includes a first traceability code of the drug to be used;

[0030] acquiring mapping information between the to-be-used drug and the user from a second medical device through the communication component;

[0031] A second traceability code of a specific to-be-used drug associated with a specific drug user is determined according to the mapping information and the index information.

[0032] The present invention further provides a data processing device, including:

[0033] A first interaction module is configured to obtain index information of a drug to be used from a first medical device, wherein the index information includes a first traceability code of the drug to be used;

[0034] A second interaction module is configured to obtain mapping information between the to-be-used drug and the user from a second medical device;

[0035] The processing module is used to determine a second traceability code of a specific to-be-used drug associated with a specific drug user based on the mapping information and the index information.

[0036] An embodiment of the present application further provides a computing device, including a memory, a processor, and a communication component;

[0037] The memory is used to store one or more computer instructions;

[0038] The processor is coupled to the memory and the communication component and is configured to execute the one or more computer instructions for:

[0039] Scan the code to obtain the first traceability code of the medicine to be used;

[0040] generating index information of the drug to be used according to the first traceability code;

[0041] The index information is provided to a computing device through the communication component, so that the computing device can determine a second traceability code of a specific drug to be used associated with a specific user based on the index information and the mapping information between the drug to be used and the user obtained from the second medical device.

[0042] The present invention further provides a data processing device, including:

[0043] The code scanning module is used to scan the code to obtain the first traceability code of the drug to be used;

[0044] An index information generating module, configured to generate index information of the drug to be used according to the first traceability code;

[0045] The interactive module is used to provide the index information to the computing device, so that the computing device can determine the second traceability code of the specific to-be-used drug associated with the specific user based on the index information and the mapping information between the to-be-used drug and the user obtained from the second medical device.

[0046] An embodiment of the present application further provides a computing device, including a memory, a processor, and a communication component;

[0047] The memory is used to store one or more computer instructions;

[0048] The processor is coupled to the memory and the communication component and is configured to execute the one or more computer instructions for:

[0049] obtaining medication user information through the communication component;

[0050] Obtaining, from a computing device via the communication component, an intermediate code corresponding to a first traceability code of the drug to be used and a distribution group to which the drug belongs;

[0051] Allocating the intermediate code to the user based on the intermediate code corresponding to the first traceability code of the drug to be used and the allocation group to which it belongs;

[0052] The mapping information between the intermediate code and the drug user is provided to the computing device through the communication component, so that the computing device decodes the intermediate code in the mapping information to determine the second traceability code of the specific drug to be used associated with the specific drug user.

[0053] The present invention further provides a data processing device, including:

[0054] An acquisition module is used to obtain information about the drug user; obtain the intermediate code corresponding to the first traceability code of the drug to be used and the distribution group to which it belongs from the computing device;

[0055] an allocation module, configured to allocate the intermediate code to the user according to the intermediate code corresponding to the first traceability code of the drug to be used and the allocation group to which it belongs;

[0056] The sending module is used to provide the mapping information between the intermediate code and the drug user to the computing device, so that the computing device decodes the intermediate code in the mapping information to determine the second traceability code of the specific to-be-used drug associated with the specific drug user.

[0057] An embodiment of the present application further provides a computing device, including a memory, a processor, and a communication component;

[0058] The memory is used to store one or more computer instructions;

[0059] The processor is coupled to the memory and the communication component and is configured to execute the one or more computer instructions for:

[0060] sending a medication query request to a computing device via the communication component, wherein the medication query request includes information of a specific medication user;

[0061] receiving, via the communication component, a second traceability code of the specific to-be-used drug associated with the specific drug user returned by the computing device, wherein the second traceability code is determined by the computing device based on a mapping relationship between the to-be-used drug and the drug user provided by a second medical device and the first traceability code of the to-be-used drug;

[0062] The specific drug to be used is obtained according to the second traceability code and distributed to the specific drug user.

[0063] The present invention further provides a data processing device, including:

[0064] a request module, configured to send a medication query request to a computing device, wherein the medication query request includes information of a specific medication user;

[0065] an acquisition module, configured to receive a second traceability code of the specific to-be-used drug associated with the specific drug user, returned by the computing device, wherein the second traceability code is determined by the computing device based on a mapping relationship between the to-be-used drug and the drug user provided by a second medical device and the first traceability code of the to-be-used drug;

[0066] The drug distribution module is used to obtain the specific drug to be used according to the second traceability code and distribute it to the specific user.

[0067] An embodiment of the present application also provides a computer-readable storage medium storing computer instructions. When the computer instructions are executed by one or more processors, the one or more processors are caused to execute the aforementioned data processing method.

[0068] In an embodiment of the present application, various medical devices involved in data processing are aggregated through a computing device, and based on the traceability code obtained for the drugs to be used, a one-item-one-code mechanism can be adopted to achieve full traceability of data processing; moreover, the medical devices no longer interact directly with each other, and each medical device cannot directly access the index information of the drugs to be used during the interaction with the computing device, which enables each medical device to carry out data processing work normally without leaking the index information of the drugs to be used, thereby improving the confidentiality of the data processing process, and can comprehensively, truthfully, objectively and effectively record and evaluate the data processing process. BRIEF DESCRIPTION OF THE DRAWINGS

[0069] The drawings described herein are used to provide a further understanding of the present application and constitute a part of the present application. The illustrative embodiments of the present application and their descriptions are used to explain the present application and do not constitute an improper limitation on the present application. In the drawings:

[0070] Figure 1 A schematic diagram of the structure of a data processing system provided by an exemplary embodiment of the present application;

[0071] Figure 2 A schematic diagram of the interaction process between the computing device 10 and the devices of various related parties during the clinical trial process provided by an exemplary embodiment of the present application;

[0072] Figure 3 An exemplary embodiment of the present application provides an interactive process between a clinical trial institution's equipment and a computing device in the drug delivery and distribution stages during a clinical trial;

[0073] Figure 4 A schematic diagram of the structure of another data processing system provided by an exemplary embodiment of the present application;

[0074] Figure 5a A flowchart of a data processing method provided by an exemplary embodiment of the present application;

[0075] Figure 5b A schematic structural diagram of a data processing device provided as an exemplary embodiment of the present application;

[0076] Figure 6a A flowchart of another data processing method provided by an exemplary embodiment of the present application;

[0077] Figure 6b A schematic structural diagram of another data processing device provided as an exemplary embodiment of the present application;

[0078] Figure 7a A flowchart of another data processing method provided as an exemplary embodiment of the present application;

[0079] Figure 7b A schematic structural diagram of another data processing device provided as an exemplary embodiment of the present application;

[0080] Figure 8a A flowchart of another data processing method provided as an exemplary embodiment of the present application;

[0081] Figure 8b A schematic structural diagram of another data processing device provided as an exemplary embodiment of the present application;

[0082] Figure 9 A schematic diagram of the structure of a computing device provided as an exemplary embodiment of the present application;

[0083] Figure 10 A schematic structural diagram of another computing device provided as an exemplary embodiment of the present application;

[0084] Figure 11 A schematic structural diagram of another computing device provided as an exemplary embodiment of the present application;

[0085] Figure 12 A schematic structural diagram of another computing device provided as an exemplary embodiment of the present application. DETAILED DESCRIPTION

[0086] To make the purpose, technical solutions, and advantages of this application more clear, the technical solutions of this application will be clearly and completely described below in conjunction with the specific embodiments of this application and the corresponding drawings. Obviously, the embodiments described are only part of the embodiments of this application, not all of them. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of this application.

[0087] With respect to the traditional blinding scheme, there are problems such as low blind bottom security and low traceability of the authenticity and integrity of the test records. In some embodiments of the present application: the various medical devices involved in data processing are aggregated through a computing device, and based on the traceability code obtained for the drugs to be used, a one-item-one-code mechanism can be adopted to achieve full traceability of data processing; moreover, the medical devices no longer interact directly with each other, and each medical device cannot directly access the index information of the drugs to be used during the interaction with the computing device, which enables each medical device to carry out data processing work normally without leaking the index information of the drugs to be used, thereby improving the confidentiality of the data processing process, and can comprehensively, truthfully, objectively and effectively record and evaluate the data processing process.

[0088] The following describes in detail the technical solutions provided by various embodiments of the present application in conjunction with the accompanying drawings.

[0089] Figure 1 This is a structural diagram of a data processing system provided by an exemplary embodiment of the present application. Figure 1 As shown, the system includes: a computing device 10 and devices of various relevant parties involved in the clinical trial, and the computing device 10 is communicatively connected with the devices of various relevant parties.

[0090] The relevant parties involved in the clinical trial include, but are not limited to, sponsors, contract research organizations (CROs), clinical trial institutions, distribution institutions, etc. Below, the various terms involved in this embodiment are explained.

[0091] The sponsor may refer to an individual, organization or institution that is responsible for initiating, managing and providing funding for clinical trials.

[0092] CRO can be an individual or an organization. CRO can sign a contract with the sponsor to perform certain tasks and work of the sponsor in clinical trials and provide a central randomization system (IWRS).

[0093] The central randomization system12 is a computer information system that provides randomization services for clinical trials. It is mainly responsible for randomly allocating drugs to subjects during the clinical trial process.

[0094] Clinical trial institutions can refer to the implementers of clinical trials. Clinical trials can be conducted by teams of researchers at all levels and with different specialties.

[0095] A subject can be a human or animal who voluntarily participates in a clinical trial and serves as a recipient of the investigational drug or as a control, such as a healthy volunteer or a patient.

[0096] In the field of clinical trials, the double-blind method is considered to be the method that can best control and reduce clinical research bias. The key foundation for the implementation of the double-blind method is blinding. This embodiment can provide a safe, efficient, and controllable blinding solution.

[0097] In actual applications, the devices of each relevant party may provide the computing device 10 with entry information such as a license certificate or other supporting documents to apply for entry to the computing device 10. The computing device 10 may verify the entry information of each relevant party and, if the verification is successful, allow the device of each relevant party to enter the computing device 10 and establish a communication link with the device of each relevant party.

[0098] In this embodiment, the computing device 10 can interact with the devices of various stakeholders and provide the interaction data required for each stakeholder's device to perform its operations. Each stakeholder's device can obtain the interaction data required for its operations from the computing device 10 to carry out its own operations. It should be noted that due to the different roles played by various stakeholders in the clinical trial, the interaction processes between the devices of different stakeholders and the computing device 10, as well as the interaction data obtained from the computing device 10, may vary. This will be explained in detail in the following embodiments.

[0099] In this embodiment, the computing device 10 can be used to store blind information in clinical trials. The blind information in clinical trials includes at least the drug code and the drug attributes to which the drug code belongs. For the devices of each relevant party, when the interaction data required by them is related to the blind information, the computing device 10 can encrypt the corresponding data in the blind information to generate the interaction data required by the devices of the relevant party, and provide the interaction data to the devices of the relevant party, so that the devices of the relevant party can carry out their own work based on the corresponding data in the blind information.

[0100] In this way, on the one hand, the devices of various parties are aggregated based on the computing device 10. Each device of each party interacts with the computing device 10 to use the corresponding data in the required blind bottom information. Direct interaction between the devices of the various parties no longer occurs, effectively avoiding the problem of blind bottom information leakage that may occur between the devices of the relevant parties. On the other hand, through the encryption mechanism, the devices of various parties cannot directly access the blind bottom information. Based on these two aspects, the security of the blind bottom information can be effectively improved.

[0101] Furthermore, in this embodiment, a drug traceability code is assigned to each minimum drug package, and a one-to-one correspondence is established between the minimum drug package and the traceability code. The drug traceability code serves to identify the minimum drug package throughout the clinical trial. Based on this one-to-one correspondence between the minimum drug package and the drug traceability code, the devices of each relevant party can also provide the recorded data related to the minimum drug package generated during operation to the computing device 10 according to the drug traceability code, allowing the computing device 10 to store the recorded data for each minimum drug package. Due to the different roles played by the devices of each relevant party in the clinical trial, the recorded data related to the minimum drug package provided by each relevant party's device may also vary. For example, taking a distribution agency as an example, the recorded data related to the minimum drug package provided by its devices includes, but is not limited to, the consignee, shipping time, arrival time, transportation temperature data, and trajectory data. Taking a clinical trial institution as an example, the recorded data related to the minimum drug package provided by its devices includes, but is not limited to, the receipt time, subject code, and medication dispensing time.

[0102] In this way, by adopting the one-item-one-code mechanism, for the same minimum package of medicine, the devices of each relevant party can upload the record data related to the minimum package of medicine to the computing device 10 based on the unified medicine traceability code, so that the computing device 10 can truly and completely record the status, processing results and other information of the minimum package of a single medicine in each link.

[0103] It is worth noting that the technical solution in this embodiment can cover multiple links in clinical trials, including blind bottom information preparation, packaging and warehousing, drug delivery, drug distribution, drug recovery or destruction, and can basically cover the entire clinical trial process. The computing device can collect recorded data of drugs at each link in the clinical trial, thereby extending drug traceability from simple tracing to the research and development stage, and realizing full flow and temperature traceability of drugs. In addition, in each link, the security of blind bottom information can be ensured to prevent blind bottom information leakage. During the clinical trial process, the interaction process between the computing device 10 and the devices of various relevant parties can be seen in the detailed description of the following embodiments.

[0104] Figure 2 A schematic diagram of the interaction process between the computing device 10 and the devices of various related parties during the clinical trial process is provided as an exemplary embodiment of the present application.

[0105] The following will describe the interaction process between the computing device 10 and the devices of each relevant party according to the multiple links included in the aforementioned clinical trial process.

[0106] Blind bottom information preparation stage;

[0107] refer to Figure 2 ,In the blind bottom information preparation link, it mainly involves the interaction process between the ,applicant’s device and the computing device 10.

[0108] In this embodiment, the medicines are packaged in minimum packages, which refer to the smallest packaging unit when sold or shipped. Each minimum package of medicines may contain one bottle / box / tablet of medicine, or may contain multiple bottles / boxes / tablets of medicine.

[0109] It is worth noting that the smallest drug package referenced in this article refers to the group of drugs within the package, not the package itself. Similarly, the same applies to medium and large drug packages provided later in this article.

[0110] In this embodiment, the applicant's equipment may include a code scanning and encryption device 11 and an application device 16 .

[0111] Optionally, after being registered with the computing device 10, the application device 16 may initiate a drug information registration request to the computing device 10 for each minimum drug package. Upon successful registration, the computing device 10 may provide a drug traceability code for each minimum drug package. Drug information includes, but is not limited to, drug name, sponsor information, drug quantity, dosage form, strength, packaging specifications, production date, expiration date, and storage and outbound times. The computing device 10 may also simultaneously record the drug information corresponding to each minimum drug package.

[0112] Optionally, the application device 16 may download the drug traceability code for the smallest package of the drug from a drug traceability code provider, such as the computing device 10. Furthermore, the application device 16 may cooperate with the traceability code provider to download the traceability code in an encrypted manner. When downloading the drug traceability code in an encrypted manner, the application device 16 may also decode the downloaded content to obtain the drug traceability code.

[0113] In actual applications, a bid client may be deployed in the bid device 16 , and the operator of the bidder may perform various operations in the interactive interface provided by the bid client to input the aforementioned various information.

[0114] In terms of physical operations, the sponsor's staff can print the drug traceability code onto a label and affix it to the corresponding smallest drug packaging to complete the coding process. Afterwards, the sponsor's staff can also physically separate the experimental group medication from the control group medication.

[0115] On this basis, the code scanning and encryption device 11 can scan the smallest package of each drug used for clinical trials and record the drug attributes (test group or control group) corresponding to each drug traceability code. Figure 2 The code scanning and encryption device 11 can be implemented in a physical form such as a PDA.

[0116] For example, the code scanning and encryption device 11 can scan the code of each drug minimum package in the experimental group partition and record the drug attributes corresponding to the drug traceability code of each drug minimum package as the experimental group. Similarly, the drug attributes corresponding to the drug traceability code of each drug minimum package in the control group partition can be recorded as the control group.

[0117] The code scanning and encryption device 11 can generate blind bottom information based on the drug attributes corresponding to each scanned drug traceability code.

[0118] In actual applications, the code scanning and encryption device 11 can encrypt the drug attributes corresponding to each drug traceability code respectively, and generate blind bottom information based on each drug traceability code and the encrypted drug attributes corresponding to each drug traceability code.

[0119] In this embodiment, the encryption method of the above-mentioned drug attributes is not limited. The code scanning and encryption device 11 can use any encryption method agreed upon with the computing device 10 to encrypt the drug attributes. For example, MD5 encryption method, etc. Among them, the encryption process using MD5 can be: first, based on the drug traceability code and drug attributes, a summary information is generated, and then the drug traceability code, drug attributes, and summary information are encrypted into a 128-bit string as the result of the encryption of the drug attributes. Of course, this is only exemplary, and this embodiment is not limited to this.

[0120] In addition, the blind bottom information includes not only the traceability code of each drug and the encrypted drug attributes corresponding to each drug traceability code, but also other drug information, such as drug name, dosage form, specifications, packaging specifications, production date, expiration date, number of test drugs, number of control drugs, etc.

[0121] In this embodiment, the code scanning and encryption device 11 can encrypt the blind bottom information and report it to the computing device 10. Among them, the code scanning and encryption device 11 can use any encryption method agreed with the computing device 10 to encrypt the blind bottom information, and this embodiment does not limit this. For example, the code scanning and encryption device 11 can use its own private key to sign the blind bottom information, and use the public key of the computing device 10 to encrypt the blind bottom information; accordingly, the computing device 10 can use the public key of the code scanning and encryption device 11 to verify the encrypted blind bottom information, and after the verification is passed, the encrypted blind bottom information can be stored. Moreover, the computing device 10 can use its own private key to decrypt the stored encrypted blind bottom information to extract relevant data in the blind bottom information.

[0122] The code scanning and encryption device 11 can also provide the blind bottom information to the computing device 10 and delete the local blind bottom information. In practical applications, an application can be deployed in the code scanning and encryption device 11 to support the above functions. Based on the application, the blind bottom information in the code scanning and encryption device 11 can be forcibly deleted to ensure the security of the blind bottom information.

[0123] Subsequently, for the blind bottom information uploaded to the computing device 10, the application device 16 can initiate a blind bottom information query request to the computing device 10, which will then return the drug traceability code and its corresponding encrypted drug attributes. Because the drug attributes are encrypted, the application device 16 can only display the drug traceability code, not the drug attributes. In practical applications, the drug traceability code can also be partially displayed, for example, by hiding the middle portion of the drug traceability code. Furthermore, the blind bottom information query request initiated by the application device 16 can include authentication information such as a digital certificate. The computing device 10 can authenticate the query permission based on this authentication information and, upon successful authentication, return the drug traceability code and its corresponding encrypted drug attributes. Consequently, the transmission of the blind bottom information occurs in an encrypted environment. The scanning and encryption device 11, as the producer of the blind bottom information, cannot retain the blind bottom information. Furthermore, the application device 16 cannot obtain the complete blind bottom information through a query. This prevents potential blind bottom information leakage from the scanning and encryption device 11 or the application device 16, thereby enhancing the confidentiality of the blind bottom information preparation process.

[0124] Furthermore, the computing device 10 can also perform blockchain encryption and storage of the blind bottom information to prevent tampering or abnormal unblinding of the blind bottom information. Blockchain encryption and storage of the blind bottom information involves multiple unblinding authorizers. Only when multiple unblinding authorizers pass verification can the blind bottom information be unblinded. Based on this, the application device 16 can also submit the information of multiple unblinding authorizers associated with the blind bottom information to the computing device 10. The unblinding authorizer information can include information such as the authorizer ID, contact information, and position. The computing device 10 can perform unblinding authentication based on the information of multiple unblinding authorizers associated with the blind bottom information, and unblind after the unblinding authentication passes.

[0125] Among them, when the computing device 10 receives a request to unblind the target blind information, it can send random verification information to multiple unblinding authorizers associated with the target blind information respectively; when the random verification information provided by all unblinding authorizers is received and the random verification information provided by all unblinding authorizers is correct, the target blind information is unblinded.

[0126] In this embodiment, the unblinding request can be initiated by the application device 16, and of course can also be initiated by other demand parties, which is not limited in this embodiment.

[0127] In this way, if emergency or final unblinding is required during the clinical trial, the normal unblinding of the blind information can be ensured based on the configuration of the unblinding authorizer by the sponsor device 16 and the unblinding authentication process of the computing device 10. In other cases of abnormal unblinding, unblinding cannot be performed. This can further ensure the security of the blind information and prevent it from being leaked in abnormal unblinding situations.

[0128] Figure 3 An exemplary embodiment of the present application provides an interactive process between the equipment of a clinical trial institution and the computing equipment in the packaging warehousing link, the drug delivery link and the drug distribution link during the clinical trial process.

[0129] The following will be combined Figure 2 and Figure 3 The packaging warehousing link, drug delivery link and drug distribution link are explained respectively.

[0130] Packaging and warehousing stage;

[0131] The packaging and warehousing process mainly involves the interaction process between the application device 16 and the computing device 10.

[0132] In terms of physical operation, the sponsor's staff can mix the test group medication and the control group medication to form a secondary package, and then form a large package. To this end, the sponsor device 16 can also apply to the computing device 10 for a drug traceability code for the secondary package and the large package, and affix the code to the secondary package and the large package respectively.

[0133] Among them, the application device 16 can scan the smallest package of the medicine, the medium package of the medicine and the large package of the medicine respectively according to the preset proportion relationship of large, medium and small packages, and record the nesting relationship between the smallest package of the medicine, the medium package of the medicine and the large package of the medicine; and provide the nesting relationship to the computing device 10.

[0134] In actual application, a mixed packaging related traceability application program can be loaded into the application device 16 to realize the packaging warehousing link.

[0135] refer to Figure 2 Sponsors can flexibly set packaging solutions based on clinical trial needs. The packaging solution includes the ratio of large, medium, and small packages. For example, a 1:2:8 ratio means that one large package contains two medium packages, and one medium package contains four smallest packages.

[0136] refer to Figure 2The sponsor can also pre-set a standard operating procedure (SOP) so that the sponsor device 16 can scan the codes of the large, medium and small packages of the medicine according to the SOP: the sponsor device 16 can scan the corresponding number (4) of the smallest packages of medicine from the mixed smallest packages of medicine according to the number of the smallest packages of medicine required for a medium package of medicine (such as 4 in the above example), put them into a medium package of medicine, and then scan the drug traceability code of the medium package of medicine to associate the smallest package of medicine with the medium package of medicine; thereafter, more smallest packages of medicine can be scanned according to the number of medium packages of medicine required for a large package of medicine (such as 2 in the above example) to pack other medium packages of medicine and record the association between other medium packages of medicine and the smallest packages of medicine under them; finally, the medium packages of medicine obtained by packing are put into a large package of medicine and the drug traceability code of the large package of medicine is scanned. Thus, a nested relationship between the smallest package of medicine, the medium package of medicine and the large package of medicine can be established.

[0137] Of course, this is only an exemplary scheme for establishing a nested relationship between drug packages. It should be understood that in this embodiment, the specification levels of drug packages are not limited to large, medium and small, but can be flexibly set as needed. For example, it can be set to two levels, four levels, etc. This embodiment is not limited to this.

[0138] Based on this, the ratio of large, medium, and small packages can be flexibly configured according to the needs of different clinical trials. Moreover, during the course of a single clinical trial, the ratio of large, medium, and small packages can be flexibly adjusted when additional drugs are needed or drug dosage optimization is required. This improves the flexibility of drug delivery.

[0139] Alternatively, the sponsor's staff can perform the nesting relationship establishment operation in an independent, video-surveilled area. In principle, staff are not allowed to bring mobile phones, cameras, or other devices into the operating room. The monitoring data generated during this process can be synchronized to the computing device 10 to serve as a true and objective record of the relevant operations.

[0140] In the process of generating the nested relationship between drug packages, the application device 16 scans the codes of all the smallest packages of drugs in the clinical trial. In this way, the application device 16 can obtain the drug traceability code of each smallest package of drugs and prepare a drug list.

[0141] The sponsor device 16 can also designate a drug storage device for the drug list and provide the drug list and designated drug storage device information to the computing device 10. Drug storage devices include, but are not limited to, cold storage rooms and freezers. The computing device 10 can pre-aggregate information from multiple drug storage devices for the sponsor to select and use. Furthermore, each drug storage device can maintain communication with the computing device 10 and synchronize its own storage temperature data with the computing device 10.

[0142] In this way, the computing device 10 can determine and record the storage temperature data of the smallest package of each medicine in the medicine list for subsequent storage temperature tracing.

[0143] Drug distribution;

[0144] The drug distribution process mainly involves the interaction between the sponsor, the distribution agency, the clinical trial institution, and the computing device 10. For ease of description, the clinical trial institution's equipment is described as "drug distribution equipment" and the distribution agency's equipment is described as "distribution management equipment."

[0145] When drugs need to be shipped, the application device 16 can scan the drug traceability code on the outermost packaging of the drugs to be shipped to generate a delivery order. The application device 16 can also select the drug distribution device 14 and the target distribution management device associated with the delivery order and provide them to the computing device 10. The delivery order includes, but is not limited to, information such as the consignee, drug quantity, packaging specifications, manufacturer, and drug traceability code.

[0146] In actual application, the outermost drug packaging to be shipped may have more than one specification, for example, the outermost drug packaging may be a medium drug packaging, a minimum drug packaging, or a large drug packaging. The code scanning and encryption device 11 can scan the visible outermost drug packaging.

[0147] Furthermore, computing device 10 can pre-integrate information from multiple delivery management devices for selection by the sponsor. Furthermore, each delivery management device can maintain communication with computing device 10 and synchronize its own transportation temperature data with computing device 10. Delivery management devices include, but are not limited to, cold chain vehicles, cold storage or freezers on transport vehicles, and so on.

[0148] The distribution management device 13 can use its own temperature recording device to generate transportation temperature data during the transportation of medicines; use its own positioning device to generate trajectory data; based on the transportation temperature data, trajectory data and other information such as the consignee, shipping time, and receipt time, it can generate transportation status information; and synchronize the transportation status information to the computing device 10.

[0149] The computing device 10 may determine and record the transportation status information corresponding to the outbound delivery order corresponding to the drug dispensing device 14 based on the transportation status information reported by the target distribution management device designated by the application device 16 for the drug dispensing device 14 .

[0150] Therefore, in this embodiment, not only the trajectory monitoring and tracing of the drugs can be achieved, but also the whole process temperature monitoring and tracing can be achieved.

[0151] During the drug transport process, both the application device 16 and the drug distribution device 14 can initiate a transport process monitoring request to the computing device 10. The computing device 10 can then return transport status information to the application device 16 and the drug distribution device 14, respectively, so that the application device 16 and the drug distribution device 14 can monitor the transport process based on the transport status information. For example, if the drug distribution device 14 determines that the transport temperature data during the drug transport process does not meet the requirements based on the monitored transport status information, it can refuse to accept the goods. For another example, if the application device 16 determines that the drug transport trajectory does not meet the requirements based on the monitored transport status information, it can promptly query the distribution management device 13.

[0152] In practical applications, if a management system capable of managing multiple distribution management devices already exists, multiple distribution management agencies can synchronize transportation temperature data and trajectory data to the management system. The management system can then obtain the identification information of the target distribution management device associated with the delivery order corresponding to the drug dispensing device 14 from the computing device 10 or the application device 16. In this way, the management system can maintain the transportation temperature data and trajectory data associated with the delivery order corresponding to the drug dispensing device 14.

[0153] Based on this, the application device 16 and the drug distribution device 14 can initiate the aforementioned transportation process monitoring request to the management system during the drug transportation process, and the management system will provide the transportation temperature data and trajectory data associated with the drug distribution device 14's corresponding delivery order, without the need for the computing device 10 to participate, which can effectively save system construction costs. In addition, after the drug transportation is completed, such as after the drug distribution device 14 confirms or rejects the delivery, the management system can provide the transportation temperature data and trajectory data associated with the drug distribution device 14's corresponding delivery order generated during the drug transportation process to the computing device 10 for storage by the computing device 10.

[0154] After confirming that the received drugs meet the requirements, the clinical trial institution can receive the goods through the drug distribution device 14.

[0155] refer to Figure 3The drug dispensing device 14 can scan the drug traceability code on the outermost drug packaging received, generate a receipt, and provide its own organization ID and receipt to the computing device 10. The computing device 10 can then compare the receipt provided by the drug dispensing device 14 with the corresponding delivery receipt provided by the application device 16. If the comparison is successful, the computing device 10 can return a receipt notification to the drug dispensing device 14. The receipt reported by the drug dispensing device 14 contains at least information such as the drug quantity and the drug traceability code.

[0156] In this way, the drug traceability code can be compared to ensure that the clinical trial institution receives the correct goods, thereby avoiding problems such as package substitution and replacement during transportation. At the same time, the computing device 10 can record the warehouse entry order of the drug distribution device 14 as inventory basis.

[0157] In addition, the drug dispensing device 14 can also designate a cold chain storage device for the outermost drug package it receives and report this to the computing device 10. The cold chain storage device can then synchronize its own temperature monitoring data with the computing device, allowing the computing device 10 to determine and record the temperature monitoring data for each drug package in the drug dispensing device 14's warehouse receipt. This allows the storage status of drugs in clinical trial institutions to be traced.

[0158] In summary, in the drug transportation link, blind information is not used, so the problem of blind information leakage will not occur in this link; moreover, the distribution management device 13, the application device 16 and the drug distribution device 14 report the record data generated in the drug transportation link to the computing device 10, so that the computing device 10 can accurately and truthfully record the processing conditions generated by these relevant parties in the drug transportation link according to the drug traceability code, providing a data basis for drug traceability.

[0159] Drug distribution;

[0160] In the drug distribution link, it mainly involves the interaction process between the drug distribution device 14 and the central randomization system 12 and the computing device 10.

[0161] In actual applications, in a clinical trial project, clinical trials are usually conducted on only one drug, and there may be multiple clinical trial institutions participating in the clinical trial, and there may also be multiple central randomization systems 12, but each clinical trial institution is usually only associated with one central randomization system 12.

[0162] For ease of description, the following description will focus on a pair of drug dispensing devices 14 and a central randomization system 12. However, it should be understood that the processing of other drug dispensing devices 14 and central randomization systems 12 in the drug dispensing process is similar.

[0163] Continuing with the drug transportation process described above, the drug dispensing device 14 can not only submit the warehouse entry form to the computing device 10, but also submit the subject code to the computing device 10. Furthermore, the computing device 10 can also provide the subject code to the central randomization system 12, or the drug dispensing device 14 can also provide the subject code to the central randomization system 12. Optionally, in actual applications, the drug dispensing device 14 can be supported to import subject codes in batches.

[0164] In this embodiment, the central randomization system 12 can randomly assign the subject code to generate an assignment result, which can include the target drug attribute assigned to the subject code or the intermediate code assigned to the subject code; and send the assignment result corresponding to the subject code to the computing device 10. The computing device 10 can then assign a drug traceability code to the subject code based on the assignment result corresponding to the subject code provided by the central randomization system 12.

[0165] The following are two optional implementation methods, each of which describes the scheme for assigning drug traceability codes to subjects.

[0166] In an optional implementation, the central randomization system 12 can randomly assign a subject code to any subject to determine the target drug attribute corresponding to the subject code, as the assignment result corresponding to the subject code. The computing device 10 can select the target drug traceability code from the drug traceability codes corresponding to the smallest unassigned drug packages with the target drug attribute in the inventory receipt reported by the drug dispensing device 14 as the drug traceability code corresponding to the smallest drug package assigned to the subject code. The number of target drug traceability codes can be flexibly set based on actual needs and can be one or more.

[0167] In this implementation, during the interaction between the central randomization system 12, the drug dispensing device 14, and the computing device 10, neither the central randomization system 12 nor the drug dispensing device 14 has access to the blind bottom information, thereby avoiding the leakage of the blind bottom information.

[0168] refer to Figure 3In another optional implementation, the computing device 10 may determine the drug traceability codes for multiple minimum drug packages received by the clinical trial institution based on the nested relationship provided by the sponsoring device 11 and the inventory receipt reported by the drug dispensing device 14, encrypt the determined drug traceability codes for the multiple minimum drug packages to obtain the intermediate codes corresponding to each of the multiple drug traceability codes, decrypt the drug attributes corresponding to each of the multiple intermediate codes from the blind bottom information, and provide the multiple intermediate codes and their corresponding drug attributes to the central randomization system 12. For any subject, the central randomization system 12 may randomly assign the subject code based on the multiple intermediate codes and their corresponding drug attributes to determine the target intermediate code corresponding to the subject code, and return the target intermediate code to the computing device 10. The computing device 10 may decrypt the target intermediate code to obtain the target drug traceability code corresponding to the target intermediate code, which serves as the drug traceability code corresponding to the minimum drug package assigned to the subject code.

[0169] The computing device 10 may provide the multiple intermediate codes and their corresponding drug attributes to the central randomization system 12 in an encrypted manner. For example, the computing device 10 and the central randomization system 12 may utilize the aforementioned public key encryption and private key signature methods to transmit the multiple intermediate codes and their corresponding drug attributes. Of course, the encryption method is not limited to this.

[0170] In this implementation, there is no direct interaction between the central randomization system 12 and the drug dispensing device 14. Moreover, the central randomization system 12 does not directly access the blind bottom information, but performs randomization based on the intermediate code, which can avoid the blind bottom information leakage problem that may occur between the central randomization system 12 and the drug dispensing device 14.

[0171] It is worth noting that in the above two implementations, the central randomization system 12 can use any existing or future randomization algorithm for randomization, such as various static randomization algorithms or dynamic randomization algorithms, and the like, without limitation herein. Furthermore, the above two implementations are merely exemplary. In this embodiment, other methods can also be used to assign drug traceability codes, and this embodiment is not limited thereto.

[0172] On this basis, the drug dispensing device 14 can initiate a subject medication query request to the computing device 10. The subject medication query request includes the target subject code and the identification information of the drug dispensing device 14. The computing device 10 can determine the drug traceability code corresponding to the minimum package of drugs allocated to the target subject based on the target subject code and the identification information of the drug dispensing device 14, and return it to the drug dispensing device 14. The main consideration here is that duplicate subject codes may appear under different central randomization systems 12. To avoid confusion, the identification information of the drug dispensing device 14 is carried in the subject medication query request, so that the computing device 10 can more quickly and accurately extract the drug traceability code corresponding to the minimum package of drugs allocated to the target subject. Of course, in some possible cases, if there is no duplication of subject codes throughout the entire clinical trial process, it is not necessary to carry the identification information of the drug dispensing device 14 in the subject medication query request.

[0173] Preferably, the above-mentioned drug traceability code allocation process can be pre-executed before the drug distribution device 14 distributes the drugs. In this way, the computing device 10 can directly extract the drug traceability code corresponding to the minimum package of drugs allocated to the target subject from the local area and return it to the drug distribution device 14, thereby effectively improving the drug distribution response speed of the drug distribution device 14.

[0174] In this case, the central randomization system 12 can provide the allocation results to the computing device 10 before the drug dispensing device 14 dispenses the drugs. Furthermore, the central randomization system 12 can perform the aforementioned randomization operation multiple times and update the allocation results stored in the computing device 10 as needed. The computing device 10 can also re-determine the drug traceability code corresponding to the subject code when the allocation results are updated.

[0175] In addition, in this case, before returning the drug traceability code corresponding to the smallest package of drugs allocated to the target subject to the drug dispensing device 14, the computing device 10 may also determine whether the drug traceability code corresponding to the smallest package of drugs allocated to the target subject is determined based on the latest allocation result of the central randomization system 12. If not, the computing device 10 obtains the latest allocation result of the central randomization system 12 and re-assigns the drug traceability code corresponding to the smallest package of drugs to the target subject. There are various ways to determine whether the allocation result is the latest. For example, the computing device 10 may compare the allocation result locally on the computing device 10 with the latest allocation result generated in the central randomization system 12 based on information such as a timestamp to determine whether the allocation result locally on the computing device 10 is the latest.

[0176] Of course, the above-mentioned drug traceability code allocation process can also be executed in real time during the drug distribution process of the drug distribution device 14, and this embodiment does not limit this.

[0177] In this embodiment, while returning the drug traceability code corresponding to the smallest package of the drug assigned to the target subject to the drug dispensing device 14, the computing device 10 can also, based on the nested relationship between the smallest package, medium package, and large package, determine the drug traceability codes of the medium package and large package to which the drug traceability code corresponding to the smallest package assigned to the target subject belongs, and return this information to the drug dispensing device 14. In practical applications, the drug dispensing device 14 can generate a drug picking instruction sheet for the target subject's code and display the drug traceability codes of the medium package and large package to which the drug traceability code corresponding to the smallest package assigned to the target subject belongs on the drug picking instruction sheet. Researchers can then retrieve medication according to the drug picking instruction sheet. In this way, the drug dispensing device 14 can use the drug traceability codes of the medium package and large package to which the drug traceability code corresponding to the smallest package assigned to the target subject belongs to locate the corresponding large package, then locate the corresponding medium package, and finally locate the required smallest package. This allows for accurate and rapid retrieval of medication for the target subject.

[0178] refer to Figure 2 and Figure 3 After the researcher obtains the medication for the target subject, the drug dispensing device 14 may also scan the drug traceability code of the smallest package of the medication obtained, associate the target subject code with the scanned drug traceability code, and report it to the computing device 10. If the computing device 10 determines that the target subject code is correct and the drug traceability code scanned by the drug dispensing device 14 is consistent with the drug traceability code corresponding to the smallest package of medication assigned to the target subject code, it will return a verification result to the drug dispensing device 14 confirming that the medication was correctly obtained. If the verification result confirms that the medication was correctly obtained, the drug dispensing device 14 may distribute the smallest package of medication to the target subject and upload a drug distribution list to the computing device 10, which includes the traceability code of the smallest package of medication that has been distributed. However, if the target subject code is incorrect or the drug traceability code scanned by the drug dispensing device 14 is inconsistent with the drug traceability code corresponding to the smallest package of medication assigned to the target subject code, the computing device 10 may issue an alarm, and the medication dispensing process will terminate. Of course, the computing device 10 can also perform other checks on the minimum package of the medicine to be distributed, such as the expiration date, etc. If there are other factors that do not meet the distribution conditions, an alarm will be issued to terminate the distribution process.

[0179] In addition, the computing device 10 can mark the drug traceability code corresponding to the minimum package of drugs coded and allocated to the target subject as having been issued based on the drug issuance list provided by the drug distribution device 14, and record the subject code corresponding to the drug traceability code; and reduce the drug inventory under the drug distribution device 14.

[0180] In the aforementioned second solution for assigning drug traceability codes to subjects, the computing device 10 can also synchronize the intermediate code of the smallest package of issued drugs to the central randomization system, allowing the central randomization system to deduct the drug inventory at the drug dispensing device 14. This ensures that the central randomization system uses the latest drug inventory at the drug dispensing device 14 as the basis for random allocation, effectively ensuring the accuracy of the allocation results.

[0181] In this embodiment, after the drug is issued to the subject, the drug distribution device 14 can also generate a clinical case record and report it to the computing device 10 according to the drug traceability code. Figure 2 In addition to its duties in the drug distribution and transportation stages, the drug dispensing device 14 can also be responsible for recording adverse reactions, one-on-one doctor consultations, subject recruitment, and subject subsidy management. The drug dispensing device 14 can also upload the recorded data generated by these tasks to the computing device 10 according to the drug traceability code. These recorded data can serve as the data basis for drug traceability.

[0182] In addition to performing the aforementioned randomization tasks, the central randomization system 12 can also interact with the computing device 10 to process drug order information. Based on the subject's change data, the central randomization system 12 can generate drug order information and provide it to the computing device 10. The computing device 10 can then send the drug order information to the sponsoring device 16 for processing. Drug order information includes, but is not limited to, information such as the drug name, dosage form, strength, packaging specifications, requester, quantity requested, and recipient. For example, if a new subject is added to a clinical trial institution, the central randomization system 12 can determine the drug quantity, name, dosage form, strength, and packaging specifications required for that institution and generate drug order information with the institution as the recipient. Furthermore, the central randomization system 12 can also generate drug order information for newly added clinical trial institutions during the course of a clinical trial. This allows sponsors to review drug order information in a timely manner and stock up on demand, thereby reducing drug waste.

[0183] In summary, during the drug distribution process, neither the central randomization system 12 nor the drug distribution device 14 has direct access to the blind information, and there is no direct interaction between the central randomization system 12 and the drug distribution device 14. This ensures the security of the blind information during the drug distribution process. Furthermore, during the drug distribution process, the central randomization system 12 and the drug distribution device 14 both report the recorded data generated by their work to the computing device 10, allowing the computing device 10 to record the handling status of each minimum drug package during the drug distribution process according to the drug traceability code, providing a data foundation for drug traceability.

[0184] Drug recovery / destruction;

[0185] The drug dispensing device 14 can also initiate a drug recall / destruction request to the computing device 10. This request includes the drug traceability code for the target drug's smallest package. The computing device 10 can then recover / destroy the target drug's smallest package based on the request. For example, the drug dispensing device 14 can initiate a drug destruction request in response to an alarm from the computing device 10 or when the drug has expired. After a clinical trial, a drug recall request can be initiated for the remaining smallest packages. The computing device 10 can also simultaneously generate recall / destruction record data and link it to the drug traceability code for the target drug's smallest package.

[0186] In addition, in the aforementioned second scheme of encoding and assigning drug traceability codes to subjects, the computing device 10 can also synchronize the drug traceability codes of the smallest packages of recovered / destroyed drugs to the central randomization system 12, so that the central randomization system 12 can promptly reduce the drug inventory under the name of the drug distribution device 14, thereby effectively ensuring the accuracy of the distribution results.

[0187] Accordingly, in this embodiment, blind bottom information is not involved in the drug recovery / destruction link, thereby avoiding the problem of blind bottom information leakage that may occur in this link; moreover, the computing device 10 can generate recovery / destruction record data and associate it with the drug traceability code of the smallest package of the target drug, providing a data basis for drug traceability.

[0188] In addition to the above-described steps of blinding information preparation, drug delivery, drug distribution, drug recovery or destruction, the blinding scheme provided in this embodiment can also cover other steps in the clinical trial process, such as follow-up. Figure 2 In this embodiment, the follow-up center system can be installed in the computing device 10. The follow-up center system can upload the recorded data generated by the follow-up work to the computing device 10 according to the drug traceability code, providing a data basis for drug traceability. Other links in the clinical trial process are not listed here.

[0189] The above describes the blinding scheme provided in this embodiment from multiple aspects of the clinical trial.

[0190] As mentioned many times above, in the blinding scheme provided in this embodiment, multiple relevant parties can report the record data generated by their work to the computing device 10, and the computing device 10 can record the processing status of each drug's minimum package during the blinding process according to the drug traceability code.

[0191] Based on this, reference Figure 2 The data processing system in this embodiment may also include a monitoring system 15, which is communicatively connected to the computing device 10.

[0192] The monitoring system 15 can monitor the physical operations such as scanning, sticking and partitioning performed by the staff of the aforementioned applicant in the process of preparing the blind bottom information, generate monitoring data, and synchronize the monitoring data to the computing device 10.

[0193] The computing device 10 can extract monitoring segments that meet preset conditions from the monitoring data according to the submission time of the blind bottom information by the code scanning and encryption device 11, and associate the extracted monitoring segments with the blind bottom information.

[0194] The monitoring system 15 may include at least one video acquisition device.

[0195] For example, the computing device 10 may take the submission time of the blind bottom information as the starting point, intercept the monitoring clips within one hour before the submission time, and associate them with the blind bottom information.

[0196] In actual applications, during the above-mentioned process of preparing blind background information, the applicant's staff operates in an independent environment with a video surveillance area. In principle, staff are not allowed to bring mobile phones, cameras and other devices into the operation room.

[0197] In terms of process, physical operations such as scanning codes, sticking codes and zoning during the preparation of blind bottom information can be performed by different staff members arranged by the applicant, so as to ensure that the entire process of preparing blind bottom information is under supervision, and avoid potential leakage caused by taking pictures with mobile phone cameras during the preparation of blind bottom information. In addition, the video surveillance of the entire blinding process can be linked one by one with the uploaded blind bottom information to serve as a real and objective record of the relevant operations.

[0198] Accordingly, based on the monitoring data, the leakage of blind bottom information that may be caused by humans can be avoided, further improving the security of the blind bottom information.

[0199] Based on the aforementioned blinding process, the computing device will collect the record data of each link in the blinding process according to the drug traceability code. Based on this, the computing device can receive a drug traceability request, which includes the target drug traceability code; the computing device can extract the record data corresponding to the target drug traceability code as the response data of the drug traceability request.

[0200] In actual applications, the computing device 10 can also configure a link identifier for the recorded data. Based on this, the drug traceability request can also include a target link identifier. The computing device 10 can extract the recorded data corresponding to the target drug traceability code under the target link as the response data of the drug traceability request.

[0201] It is worth noting that, in this embodiment, the initiator of the drug tracing request is not limited, and any object that has a drug tracing request and has drug tracing authority can serve as the initiator of the drug tracing request.

[0202] Of course, in this embodiment, the computing device can also use other record formats to store the record data corresponding to each minimum package of each drug according to the drug traceability code, and this embodiment does not limit this. Accordingly, different traceability conditions can also be set in the drug traceability request to accurately and quickly trace the drug.

[0203] Accordingly, in this embodiment, based on the one-item-one-code mechanism, multiple relevant parties can report the record data generated by their work to the computing device, so that the computing device can record the handling status of each drug's smallest package during the clinical research process in a true, objective, effective and complete manner according to the drug traceability code, thereby supporting full traceability of the drug.

[0204] The following describes a detailed blinding protocol using the example of a sponsor entrusting a clinical trial institution to conduct a drug clinical trial. The sponsor's equipment includes a code scanning and encryption device and Device A, while the clinical trial institution's equipment is referred to as Device B.

[0205] All parties involved in the clinical trial (sponsor, CRO, clinical trial institution, distribution unit, etc.) must authenticate their identities on the computing device. At the same time, each party must add institutions with whom they have clinical trial dealings to their own dealings queue list. The sponsor's device A is equipped with a dedicated client, and the sponsor uses this client to authenticate its identity to the computing device. After passing the authentication, the client can submit the corresponding drug clinical trial license or other supporting documents to register the clinical trial drug information. Once the registration is approved, the traceability code for the clinical trial drug, which is a one-to-one code, can be applied for, downloaded, and decrypted to obtain the traceability code. The traceability code for each minimum package applied for can then be printed onto a label. The experimental and control group drugs are physically partitioned, and the traceability codes are affixed to the minimum packages of the experimental and control group drugs, respectively, according to demand, completing the coding work for all trial drugs.

[0206] The operator of the sponsor can also use a dedicated code scanning and encryption device to scan the code of the test group medication and the control group medication respectively. In this way, the code scanning and encryption device can collect the corresponding code scanning files of the test group medication and the control group medication, and record the drug attributes corresponding to each traceability code (test group or control group). Then, the code scanning and encryption device can immediately merge the two files generated by the code scanning to form an encrypted clinical drug blind background file, upload it to the computing device at the same time, and automatically delete the local drug blind background file and cache to ensure that the drug blind background file of clinical medication is not leaked.

[0207] For drug blinding files uploaded to the traceability system, sponsors must log in to the client with their digital certificate to view them. The computing device will return query results to Device A. In the query results, the traceability codes and the drug attributes (experimental or control group) corresponding to each code are directly hidden with "************." Blockchain-encrypted evidence is also stored. The drug blinding files are linked to authorized unblinding personnel (no fewer than two individuals, primarily personnel from institutions involved in the clinical trial, and, if necessary, authorized personnel from the relevant regulatory agency). This is used in the event of emergency or final unblinding during the clinical trial, ensuring that all parties involved clearly understand that an unblinding event has occurred. The computing device will randomly issue different random verification codes to the authorized unblinding personnel and verify the random verification codes entered by the authorized unblinding personnel. The computing device can only perform emergency or final unblinding operations when the authorized unblinding personnel enter the different random verification codes issued to the authorized unblinding personnel. This ensures the security of the unblinding at all times and ensures that the unblinding is only truly known when emergency or final unblinding is required.

[0208] After labeling and scanning the test and control group medications, the two groups are then mixed to form medium packages, with multiple medium packages forming a large package. The previously applied traceability codes are affixed to the medium and large packages, respectively. Then, using the mixed-pack traceability application (installable on device A), the ratio of large, medium, and small packages is set. For example, 1:2:8 means there are two medium packages in one large package, and each medium package contains four small packages. Using the code scanning device included in device A, the smallest package codes of the mixed test and control group medications are first scanned. After scanning the traceability codes of four boxes of medication, device A will automatically prompt you to scan the medium package codes of the four smallest packages. After scanning, the next scan of the four smallest packages begins. After scanning the four smallest packages, the medium package codes corresponding to these four smallest packages are scanned. Once all scans are complete, the code encryption device automatically prompts you to scan the large package codes corresponding to the two medium packages. Throughout the entire process, if the wrong code is scanned, the code scanning and encryption device will automatically prompt, ensuring the association between large, medium, and small packages. This creates a large, medium, and small package association file, which is uploaded to the computing device and automatically generates a drug list. This is then linked to the corresponding cold chain storage devices for temperature traceability. The main purpose of establishing this association is to facilitate subsequent scanning of the large box code in each step. This allows users to obtain the medium and minimum package codes contained within the large box code without unpacking the box, improving delivery efficiency.

[0209] The operations of labeling and scanning drug codes for the above-mentioned experimental group and control group drugs to form drug blind documents and packaging associations shall be performed by the sponsor in an independent environment with video surveillance area. Operators are not allowed to bring mobile phones, cameras and other devices into the operation room in principle. In terms of process, printing traceability codes, labeling, scanning codes and establishing packaging associations shall be performed by different operators respectively, so as to ensure that the generation of drug blind documents and the aforementioned scanning and packaging association processes are under supervision throughout, avoiding potential leakage caused by taking photos with mobile phones, cameras, etc. during the formation of drug blind documents, and the video surveillance of the entire blinding process can be associated one by one with the uploaded drug blind documents to serve as a true and objective record of the relevant operations.

[0210] Once the sponsor decides to ship clinical trial medications (including those for the experimental and control groups) to the clinical trial institution, Device A can scan the code using a barcode scanner to generate a delivery order, which it can then upload to the computing device. The sponsor can also select the clinical trial institution and delivery unit, as well as the cold chain temperature device corresponding to the delivery order, in the client to link it to the aforementioned delivery order.

[0211] After that, the distribution unit can deliver the drugs. After the distribution unit delivers the clinical trial drugs to the clinical trial institution, the sponsor or clinical trial institution can use a dedicated monitoring program to view the temperature and location during transportation, and can predict the arrival time of the drugs in advance to better make work arrangements. When the drugs are delivered, if the drugs are confirmed to be within the specified temperature curve range, click Confirm Receipt. If the clinical trial drugs are considered problematic, click Reject Receipt and return them to the upstream shipping agency. For clinical trial drugs, whether confirmed or rejected, the corresponding transportation temperature records and transportation tracks can be automatically uploaded to the computing device.

[0212] For clinical trial drugs that have been confirmed to have been received, the clinical research institution shall use a code scanning device to scan the code to receive the goods, generate a storage document, and upload it to the computing device. At the same time, the traceability code of the received goods is verified with the computing device to ensure that the received goods are the goods sent by the upstream institution, avoid the substitution of packages and goods in the middle process, and supervise the entire transportation process to ensure that the temperature of the drugs during transportation is within the specified range. Once the clinical trial institution successfully uploads the storage document to the computing device, the clinical trial institution can choose to associate the storage document with the corresponding cold chain storage equipment (cold storage, refrigerator or insulated box) to monitor the storage temperature in real time to ensure the storage safety of clinical trial drugs, especially the storage safety of drugs with cold chain requirements.

[0213] For clinical trial drugs that have been successfully put into storage, the association relationship of the traceability codes contained in the storage documents is obtained through computing equipment, and the minimum package traceability code is obtained through the association relationship. The minimum package traceability code is then converted to generate a unique drug index code. The unique drug index code and the drug attributes corresponding to the minimum package traceability code and related drug information are interacted with the central randomization system.

[0214] After receiving the unique drug index codes and drug-related information pushed from the traceability system, the central randomization system assigns a unique subject code to each subject based on the patient's randomization result. This code is then verified with the central randomization system to obtain the unique drug index code corresponding to the subject's unique code. After the computing device decrypts the obtained unique drug index code, the last six digits of the drug traceability code are displayed on the clinical trial institution's client, prompting the clinical trial institution to retrieve the box of drug with the last digit of the drug. After retrieving the drug, the clinical trial institution scans the traceability code again through the client, enters or scans the subject's unique code, and then verifies with the traceability system that the drug and subject unique code issued by the traceability system are within the validity period. If they are incorrect, an alarm will be issued, and the drug will not be distributed to the subject. If the confirmation is successful, the traceability system automatically deducts the quantity of drugs ordered by the institution and calibrates the traceability code of the drugs already issued. It also records the subject's unique code and the traceability code of the drug used with that code, and returns the successful clinical drug issuance information to the central randomization system. The traceability system supports real-time interaction with the central randomization system for order information on clinical trial drugs.

[0215] Based on the dynamic changes in the actual number of subjects enrolled in clinical trial institutions, new or supplemental clinical trial drugs are needed. The central randomization system interacts with the traceability system in real time to push order information for the new clinical trial drugs (order information includes the generic name of the drug, dosage form, specifications, packaging specifications, requester, required quantity, consignee information, etc.) to the sponsor and promptly remind the sponsor's relevant contact person to pay attention to the new order information. The sponsor can view the specific new clinical trial drug order information through the sponsor traceability client provided by the traceability system, prepare stocks as needed, and reduce waste.

[0216] The computing device also supports the recycling and destruction of clinical trial drugs. For unused drugs at clinical trial institutions, such as those past their expiration date, they can be returned by scanning a QR code on the client. A return order is uploaded to the computing device and simultaneously sent back to the upstream manufacturer. For clinical trial drugs that have expired or require destruction, a destruction order is generated by scanning a QR code and uploaded to the computing device.

[0217] In summary, the blinding scheme provided in this embodiment can aggregate the relevant parties involved in the clinical trial on a unified platform through computing equipment, and jointly realize the safe and efficient one-to-one traceability and temperature traceability of the entire process of clinical trial drugs. Moreover, for trials with long clinical trial cycles, the drugs used in clinical trials can be supplemented, coded, grouped, distributed, and distributed according to the foreseeable drug demand or order each time, solving practical problems in the industry and making the source and destination of clinical trial drugs traceable. At the same time, by adopting appropriate encryption technologies and mechanisms, the collection, storage, transmission, and viewing of blind bottom information in the corresponding links are kept confidential, controllable, and highly secure. The relevant parties can carry out trial-related work normally and ensure that the blind bottom is not leaked in advance. Technical means are used to ensure that clinical trial drugs can be recorded and evaluated truthfully, objectively, and effectively during the clinical trial process. Together with all relevant parties, we contribute to the subsequent launch of effective, safe, and quality-assured drugs to the market.

[0218] The above describes the principles of the data processing system from the perspective of a blind coding scenario. However, the data processing solution in this case is not limited to blind coding scenarios and can also be applied to other scenarios. The following provides a more general data processing solution.

[0219] Figure 4 A structural diagram of another data processing system provided by an exemplary embodiment of the present application. Figure 4 , the data processing system includes: a computing device 40, and a first medical device 41 and a second medical device 42 communicatively connected to the computing device 40;

[0220] The first medical device 41 is configured to obtain a first traceability code for the drug to be used, generate index information of the drug to be used based on the first traceability code, and provide the index information to the computing device 40;

[0221] A second medical device 42 is configured to distribute the drug to be used to the user and provide mapping information between the drug to be used and the user to the computing device 40;

[0222] The computing device 40 is configured to determine a second traceability code of a specific to-be-used drug associated with a specific drug user based on the mapping information and the index information.

[0223] The index information includes the first traceability code of the drug to be used. Of course, in different application scenarios, the index information may also include other information required in the application scenario, which is not limited in this embodiment.

[0224] In this embodiment, the first medical device 41 and the second medical device 42 may comprise biological laboratory equipment. Furthermore, in different application scenarios, the data processing tasks of the first medical device 41 and the second medical device 42 may not be identical. For example, in the aforementioned blinded scenario, the first medical device 41 may comprise an application device, while the second medical device 41 may comprise a central randomization system.

[0225] In addition, in this embodiment, the user can be a human or an animal. For example, in the above-mentioned blinding scenario, the user can include a subject in a clinical trial.

[0226] In this embodiment, the computing device 40 and the second medical device 42 may use various implementation methods to determine the second traceability code of the specific to-be-used drug associated with the specific drug user.

[0227] In one implementation:

[0228] The computing device 40 is also used to encode the first traceability code of the unused drug in the index information into an intermediate code, and provide the intermediate code to the second medical device 42; the second medical device 42 is used to assign the intermediate code to the user, and provide the mapping information between the intermediate code and the user to the computing device 40; the computing device 40 can determine the specific intermediate code corresponding to the specific user based on the mapping information, and decode the specific intermediate code to obtain the second traceability code.

[0229] The encoding method may be the MD5 encryption method mentioned above.

[0230] Among them, if the index information includes the first traceability code of the drug to be used and the allocation group to which it belongs; the computing device 40 can provide the intermediate code corresponding to the drug to be used and the allocation group to which it belongs to to the second medical device 42; the second medical device 42 can group the drug users based on the types of preset allocation groups; under each allocation group, the intermediate code under the allocation group is respectively allocated to the drug users under the allocation group to generate mapping information between the intermediate code and the drug user.

[0231] For example, in the aforementioned blind coding scenario, the index information can be used as the blind bottom information, and the allocation group can include the experimental group or the control group. Of course, in other application scenarios, the index information and allocation combination can be flexibly configured.

[0232] Accordingly, the intermediate code can ensure the normal data processing of the second medical device 42 and avoid direct access to the index information by the second medical device 42, that is, the second medical device 42 cannot obtain the complete index information, which can effectively improve the security of the index information.

[0233] In another implementation:

[0234] If the index information includes the first traceability code of the to-be-used drug and the allocation group to which it belongs; the second medical device 42 can group the drug users based on the preset group types to determine the mapping information between the drug users and the allocation groups, and provide it to the computing device 40; the computing device 40 can select the second traceability code from multiple first traceability codes under the allocation group associated with the specific drug user based on the index information and the mapping information between the drug users and the allocation groups.

[0235] For example, in the aforementioned blinded scenario, the second medical device could include a central randomization system, the index information could serve as the blinding information, and the allocation groups could include either a test group or a control group. Of course, in other application scenarios, the index information and allocation combinations can be flexibly configured.

[0236] Of course, the above two implementations are exemplary. In this embodiment, the method for determining the second traceability code is not limited thereto.

[0237] In the above scheme for determining the second traceability code, when the index information includes the first traceability code of the drug to be used and the distribution group to which it belongs, the first medical device 41 may generate the index information in advance and provide it to the computing device 40 .

[0238] In this embodiment, the first medical device 41 may include a first device 410 and a second device 411. In terms of physical implementation, the first device 410 may be implemented as a physical machine, server, etc.; the second device 411 may be implemented as a portable device such as a PDA that has code scanning and data processing capabilities.

[0239] Based on this, the first device 410 can obtain the first traceability code for the pending drugs; the second device 411 can be used to scan the code of the pending drugs; based on the first traceability code of the pending drugs, index information of the pending drugs is generated and provided to the computing device 40.

[0240] During the process of generating the index information of the drugs to be used, the second device 411 may determine the allocation group to which the drugs to be used belong; and generate the index information of the drugs to be used according to the first traceability code of the drugs to be used and the allocation group to which they belong.

[0241] In a possible design solution, the second device 411 may encrypt the respective groups to which the drugs to be used belong, and generate index information based on the first traceability code of the drugs to be used and the encrypted allocation group.

[0242] On this basis, the second device 411 may encrypt and send the index information to the computing device 40;

[0243] After the index information is sent to the computing device 40 , the local data related to the index information is deleted.

[0244] In actual applications, an application can be pre-installed in the second device 411, and a forced deletion module can be configured in the application. Based on the forced deletion module, after the second device 411 sends the index information to the computing device 40, its local data related to the index information can be forcibly deleted.

[0245] In this way, the second device 411, as the preparer of the index information, does not save the index information. When the second device 411 or the first device 410 subsequently desires to view the index information, the allocation group in the index information returned by the computing device 40 is in an encrypted state, that is, the allocation group is invisible. Therefore, the second device 411 or the first device 410 will not be able to fully view the index information, which can avoid the possible index information leakage problem of the second device 411 or the first device 410.

[0246] In practical applications, an application can be pre-loaded in the second device 411 to support the second device 411 in executing the index information preparation process. Having the second device 411 independently perform the index information preparation process can improve operational convenience and further enhance the security of the index information.

[0247] In addition, it is worth noting that for other actions performed by the first medical device 41, one or more applications can be configured as needed, and each action of the first medical device 41 can be implemented by loading and running the one or more applications. Among them, except for the aforementioned index information preparation process, which is preferably performed by the second device 411, the other one or more applications can preferably be all loaded on the first device 410. Of course, they can also be all loaded on the second device 411, or loaded on the first device 410 and the second device 411 as needed, and this embodiment is not limited to this.

[0248] For ease of description, the following will not specifically distinguish on which device each action is performed, and the technical solution will be described from the perspective of the first medical device 41.

[0249] Taking into account the stringent requirements of the storage temperature of the drugs to be used, in this embodiment, the data processing system may also include multiple drug storage devices, and the computing device 40 may integrate the information of the multiple drug storage devices in advance for selection and use by the first medical device 41.

[0250] Based on this, the first medical device 41 can provide the computing device 40 with information about the drug storage device designated for the pending drug. Multiple drug storage devices can synchronize their own storage temperature data with the computing device 40; the computing device 40 can determine the storage temperature data corresponding to each pending drug based on the storage temperature data provided by the multiple drug storage devices. This allows the storage temperature of the pending drug on the first medical device 41 side to be traced. To prevent the index information from being abnormally queried in other circumstances, in this embodiment, the first medical device 41 can encrypt and store the query information on the blockchain. The first medical device 41 can configure multiple query authorizers for the index information and provide the information of the multiple query authorizers to the computing device 40. The computing device 40 is also configured to, upon receiving a query request for the index information, issue a query authentication to the multiple query authorizers based on the information of the multiple query authorizers associated with the index information, and allow the query operation on the index information if the query authentication information returned by the multiple query authorizers meets preset conditions.

[0251] In this embodiment, the medicines to be used are distributed and sold in the smallest medicine package. In other words, the medicines to be used are distributed and sold in the smallest medicine package. In this embodiment, the smallest medicine package is also used as the processing unit.

[0252] The first medical device 41 can initiate a first traceability code acquisition request for the smallest package of the drug to the computing device 40; generate index information of the smallest package of the drug based on the first traceability code as index information of the drug to be used; the computing device 40 is also used to generate a first traceability code for the smallest package of the drug and provide it to the first medical device 41.

[0253] In this embodiment, other specifications of drug packaging can also be configured, for example, medium drug packaging, etc. Drug packaging of different specifications can be nested with each other, for example, 4 smallest drug packages are nested in a medium drug packaging, and 2 medium drug packagings are nested in a large drug packaging.

[0254] In actual applications, the drugs to be used can be flexibly packaged according to the drug distribution or transportation needs and in accordance with the drug packaging of various specifications.

[0255] To this end, the first medical device 41 is also used to initiate a second traceability code acquisition request to the computing device 40 for other specifications of drug packaging; the computing device 40 is used to generate a third traceability code for other specifications of drug packaging and provide it to the first medical device 41.

[0256] In addition, the first medical device 41 is also used to: determine the number of drug packages of various specifications under the maximum package of a single drug according to the proportional relationship between the preset drug packaging specifications, and generate nesting information between the drug packages according to the traceability codes and physical nesting relationships of the drug packages of various specifications; and provide the nesting information to the computing device 40 so that the computing device 40 can save the nesting information.

[0257] For example, in the aforementioned blind coding scenario, the first medical device 41 may include a code scanning and encryption device and an application device, thereby generating a nested relationship between drug packages of various specifications in clinical trials.

[0258] Afterwards, the drugs to be used can be transported and distributed.

[0259] refer to Figure 4 ,In this embodiment, the data processing system further includes a third medical device 43, at least one distribution management device;

[0260] The first medical device 41 is also used to determine the target drug that needs to be allocated to the third medical device 43 from the waiting drugs, generate a delivery note corresponding to the third medical device 43 based on the traceability codes of the multiple outermost drug packages formed by the target drug; specify the target distribution management device 44 for the delivery note; and provide information of the delivery note and the target distribution management device to the computing device 40.

[0261] The target delivery management device 44 is configured to report its own transportation status information to the computing device. This transportation status information includes transportation temperature data and / or trajectory data. The computing device 40 can determine the transportation status information corresponding to the delivery order corresponding to the third medical device 43 based on the transportation status information reported by the target delivery management device 44. Of course, the transportation status information may also include information such as the consignee, shipping time, transportation humidity data, lighting data, and receipt time.

[0262] Based on this, the first medical device 41 and the third medical device 43 can be used to initiate a transportation process monitoring request to the computing device 40 respectively, and the transportation process monitoring request includes the information of the outbound delivery order, such as the order number of the outbound delivery order; and the computing device 40 is used to provide the transportation status information corresponding to the outbound delivery order to the first medical device 41 and the third medical device 43 respectively, such as transportation temperature data and / or trajectory data, etc., in response to the transportation process monitoring request.

[0263] The above describes the management of multiple delivery management devices by the computing device 40. In some possible designs, multiple delivery management devices can be managed by a single management system. Accordingly, the computing device 40 can provide the management system with the identification information of the delivery order corresponding to the third medical device 43 and the target delivery management device associated with the delivery order. Furthermore, the management system can collect the transportation status information reported by the target delivery management device and associate it with the delivery order. Based on this, the first medical device 41 and the third medical device 43 can each initiate a transportation process monitoring request to the management system to obtain the transportation status information corresponding to the delivery order from the management system.

[0264] After the delivery process is completed, the third medical device 43 can be received.

[0265] If there are multiple second medical devices 42, the computing device 40 may predetermine the target second medical device associated with the third medical device 43. For example, in the aforementioned blinding scenario, each clinical trial institution is associated with only one central randomization system, and drug allocation operations for that clinical trial institution must be performed by the central randomization system associated with that clinical trial institution.

[0266] Based on this, third medical device 43 can scan the traceability code on the outermost drug packaging it receives, generate a receipt, and provide it to computing device 40. Computing device 40 can then compare the receipt provided by third medical device 43 with the corresponding delivery note provided by first medical device 41. If the comparison is successful, computing device 40 can return a receipt notification to third medical device 43. Computing device 40 can also associate and store the receipt information with that of third medical device 43.

[0267] The computing device can determine the first traceability code of each smallest package of medicine received by the third medical device 43 based on the aforementioned nested information and the traceability code of at least one outermost layer of medicine packaging in the inventory receipt corresponding to the third medical device 43; and encrypt each determined first traceability code and send it to the target second medical device corresponding to the third medical device 43.

[0268] The target second medical device can obtain the information of the user under the third medical device 43, and distribute the minimum packages of each drug received by the third medical device to the user under the third medical device, so as to generate mapping information between the drugs to be used corresponding to the third medical device and the users.

[0269] Following the first of the two implementations for determining the second traceability code of a specific drug user between the computing device 40 and the second medical device 42 provided above: in this case, the computing device may encode the first traceability code of each minimum drug package received by the third medical device 43 into an intermediate code and, based on the index information, determine the allocation group to which each intermediate code belongs. The encoded intermediate code and the allocation group to which each intermediate code belongs are provided to the target second medical device. The target second medical device may assign each intermediate code provided by the computing device to the drug user under the name of the third medical device 43, thereby generating mapping information between the intermediate code and the drug user, which serves as the mapping information between the to-be-used drug corresponding to the third medical device 43 and the drug user. The computing device 40 may then, through the aforementioned intermediate code decoding operation, convert the mapping information between the intermediate code and the drug user into mapping information between the traceability code and the drug user for query purposes.

[0270] In addition, if the user of the third medical device 43 changes, the target second medical device can generate drug order information based on the medication needs of the incremental user and send the drug order information to the computing device 40. Of course, if a new clinical trial institution is newly associated with the target second medical device, the target second medical device can also generate drug order information based on the incremental user of the third medical device 43.

[0271] When it is necessary to distribute drugs, the third medical device 43 may also send a drug query request to the computing device 40, which includes information about a specific drug user and identification information of the third medical device 43; the computing device 40 is used to determine the second traceability code of the specific drug to be used associated with the specific drug user based on the information about the specific drug user and the identification information of the third medical device 43, and return it to the third medical device 43.

[0272] In addition, the computing device 40 is further configured to determine the traceability codes of the drug packages of various levels of specifications to which the specific to-be-used drug associated with the specific user belongs, and return the codes to the third medical device 43 .

[0273] In this way, the third medical device 43 can obtain the traceability codes of the drug packaging of each level of specifications to which the specific drug to be used belongs, and can query the drug packaging of each specification step by step based on these traceability codes, so as to find the smallest drug packaging of the specific drug to be used more quickly.

[0274] After the smallest package of the medicine is obtained, the third medical device 43 is further configured to scan the first traceability code on the smallest package of the medicine obtained and upload the scan result to the computing device 40;

[0275] The computing device 40 is further configured to return a verification result indicating that the medication is correctly taken to the third medical device 43 when it is determined that the code scanning result of the third medical device 43 is consistent with the second traceability code assigned to the specific medication user.

[0276] In addition, after the drug is issued, the third medical device 43 is also used to:

[0277] After the specific to-be-used drug associated with the specific user is issued, a drug issuance list is generated, the drug issuance list including the second traceability code of the specific drug and information of the specific user; the drug issuance list is uploaded to the computing device 40;

[0278] The computing device 40 is further configured to record information of a specific drug user corresponding to the second traceability code, and to reduce the inventory of unused drugs under the third medical device 43 .

[0279] In addition, following the first of the two implementation methods of determining the second traceability code of a specific drug user between the computing device 40 and the second medical device 42 provided in the previous article: the computing device 40 can also encode the second traceability code into an intermediate code after the drug is issued and provide it to the second medical device, so that the second medical device can reduce the inventory of unused drugs under the third medical device.

[0280] In this way, not only the processing process of the third medical device 43 on the drugs to be used can be recorded, but also the inventory synchronization between the third medical device 43 and the computing device 40 can be ensured.

[0281] In this embodiment, the third medical device 43 is further configured to: generate a clinical case record corresponding to a specific drug user, associate the clinical case record with the second traceability code corresponding to the specific drug user; and upload the clinical case record to the computing device 40 according to the second traceability code corresponding to the specific drug user. In this way, the computing device 40 can collect the clinical case record according to the first traceability code of the drug to be used.

[0282] In this embodiment, the third medical device 43 is further used to: initiate a drug recovery / destruction request to the computing device 40, and the drug recovery / destruction request includes a target traceability code; the computing device 40 is further used to send a drug recovery / destruction notification to the first medical device 41 according to the drug recovery / destruction request, and the drug recovery / destruction notification includes a target traceability code; after the first medical device 41 returns a completion notification, the target traceability code is marked as recovered / destroyed.

[0283] In addition, following the first of the two implementation methods of determining the second traceability code of a specific drug user between the computing device 40 and the second medical device 42 provided in the previous article: the computing device 40 can also encode the target traceability code into an intermediate code and provide it to the second medical device after the drug is recovered / destroyed, so that the second medical device can reduce the inventory of unused drugs under the third medical device.

[0284] Based on the above data processing process, the computing device 40 can collect the record data generated at each stage of the data processing process, and can save the record data according to the first traceability code of the drug to be used.

[0285] Based on this, in this embodiment, the computing device 40 is further configured to:

[0286] Receive a drug tracing request, which includes a target tracing code;

[0287] Extract the record data corresponding to the target traceability code from the local machine to respond to the drug traceability request.

[0288] In addition, in this embodiment, the data processing system may further include a monitoring device 45; the monitoring device 45 is used to: monitor the manual operation during the generation of the index information, generate monitoring data, and synchronize the monitoring data to the computing device;

[0289] The computing device 40 is configured to determine a submission time of the index information; extract monitoring segments that meet preset conditions from the monitoring data, and associate the extracted monitoring segments with the index information.

[0290] Based on monitoring data, the leakage of index bottom information that may be caused by humans can be avoided, further improving the security of blind bottom information.

[0291] It is worth noting that the technical details involved in each embodiment of the above data processing system can be found in Figure 1 The description of the embodiment related to the data processing system shown in FIG. Figure 1 The technical details provided by the data processing system shown are merely technical implementations in a specific application scenario and should not cause any loss of the protection scope of the data processing system provided by this embodiment.

[0292] Figure 5a A flowchart of a data processing method provided by an exemplary embodiment of the present application is provided. Figure 5a The data processing method provided in this embodiment can be executed by a data processing device, which can be implemented as software or a combination of software and hardware. The data processing device can be integrated into the computing device in the aforementioned embodiment. Figure 5a As shown, the method includes:

[0293] Step 500: Obtain index information of the drug to be used from a first medical device, where the index information includes a first traceability code of the drug to be used;

[0294] Step 501: Obtain mapping information between a drug to be used and a user from a second medical device;

[0295] Step 502: Determine a second traceability code of a specific to-be-used drug associated with a specific drug user based on the mapping information and the index information.

[0296] In an optional embodiment, the step of determining the second traceability code of the specific to-be-used drug associated with the specific drug user based on the mapping information and the index information includes:

[0297] encoding the first traceability code of the to-be-used drug in the index information into an intermediate code, and providing the intermediate code to the second medical device so that the second medical device can assign the intermediate code to the drug user;

[0298] Obtaining mapping information between the intermediate code provided by the second medical device and the medication user;

[0299] According to the mapping information, the specific intermediate code corresponding to the specific drug user is determined, and the specific intermediate code is decoded to obtain a second traceability code.

[0300] In an optional embodiment, the index information includes the first traceability code of the drug to be used and the distribution group to which it belongs. The method further includes:

[0301] The allocation group to which the drug to be used belongs is provided to the second medical device, so that the second medical device generates mapping information between the intermediate code and the user according to the intermediate code corresponding to the drug to be used and the allocation group to which it belongs.

[0302] In an optional embodiment, the index information includes a first traceability code of the to-be-used drug and the distribution group to which it belongs. The step of determining a second traceability code of a specific to-be-used drug associated with a specific user based on the mapping information and the index information includes:

[0303] obtaining mapping information between medication users and allocation groups provided by a second medical device;

[0304] Based on the index information and the mapping information between the medication users and the allocation groups, a second traceability code is selected from a plurality of first traceability codes under the allocation group associated with the specific medication user.

[0305] In an optional embodiment, the index information is used as blind information in a clinical trial, and the allocation group includes an experimental group or a control group.

[0306] In an optional embodiment, the method further comprises:

[0307] Receiving the first medical device to designate a drug storage device for drugs to be used;

[0308] receiving storage temperature data reported by at least one drug storage device;

[0309] According to the storage temperature data reported by at least one medicine storage device, the storage temperature data corresponding to each of the medicines to be used is determined.

[0310] In an optional embodiment, the method further comprises:

[0311] Upon receiving a query request for the index information, issuing a query authentication to the plurality of query authorizers based on information of the plurality of query authorizers associated with the index information by the first medical device;

[0312] When the query authentication information returned by multiple query authorizers meets the preset conditions, the query operation on the index information is allowed.

[0313] In an optional embodiment, the medicine to be used is in the smallest medicine package unit, and the method further includes:

[0314] Receiving a first traceability code acquisition request initiated by a first medical device for a minimum package of a drug;

[0315] Generate the first traceability code for the smallest package of medicine and provide it to the first medical device.

[0316] In an optional embodiment, the method further comprises:

[0317] receiving a second traceability code acquisition request initiated by the first medical device for drug packaging of other specifications;

[0318] A third traceability code is generated for each of the other specifications of the drug packaging and provided to the first medical device.

[0319] In an optional embodiment, the method further comprises:

[0320] receiving a delivery order generated by the first medical device for the third medical device, the delivery order including a traceability code of at least one outermost drug package of a target drug among the drugs to be used that needs to be allocated to the third medical device;

[0321] receiving transport status information reported by the target distribution management device specified by the first medical device for the outbound delivery order, the transport status information including transport temperature data and trajectory data;

[0322] Determine the transportation status information corresponding to the outbound order based on the transportation status information reported by the target distribution management device.

[0323] In an optional embodiment, the method further comprises:

[0324] receiving a transport process monitoring request initiated by the first medical device or the third medical device, wherein the transport process monitoring request includes information of a delivery order corresponding to the third medical device;

[0325] The transportation status information corresponding to the outbound order is used as the response result of the transportation process monitoring request.

[0326] In an optional embodiment, the method further comprises:

[0327] receiving a delivery order generated by the first medical device for the third medical device, the delivery order including a traceability code of at least one outermost drug package of a target drug among the drugs to be used that needs to be distributed to the third medical device;

[0328] The identification information of the delivery order and the identification information of the target delivery management device specified by the first medical device for the delivery order are provided to a management system for managing multiple delivery management devices, so that the management system can determine the transportation status information corresponding to the delivery order.

[0329] In an optional embodiment, when there are multiple second medical devices, the method further includes:

[0330] Obtaining a warehouse entry form reported by the third medical device, the warehouse entry form including a traceability code of at least one outermost drug package received by the third medical device;

[0331] Determining, based on the nesting information between the drug packages of various specifications provided by the first medical device, a first traceability code of the smallest drug package contained in each of at least one outermost drug package;

[0332] The determined first traceability codes are encrypted and sent to the target second medical device corresponding to the third medical device, so that the target second medical device can distribute the minimum packages of each drug received by the third medical device to the users under the name of the third medical device, so as to generate mapping information between the drugs to be used corresponding to the third medical device and the users.

[0333] In an optional embodiment, the method further comprises:

[0334] receiving drug order information provided by the target second medical device, where the drug order information is generated by the target second medical device based on incremental drug demand of users under the name of the third medical device;

[0335] The drug order information is sent to the first medical device, so that the first medical device can prepare drugs according to the drug order information.

[0336] In an optional embodiment, the method further comprises:

[0337] Receive temperature monitoring data reported by a third medical device according to a third traceability code of at least one largest package of medicine during storage of the at least one largest package of medicine.

[0338] In an optional embodiment, the method further comprises:

[0339] receiving a medication query request sent by a third medical device, the medication query request including information of a specific medication user and identification information of the third medical device;

[0340] According to the information of the specific drug user and the identification information of the third medical device, a second traceability code of the specific drug to be used associated with the specific drug user is determined and returned to the third medical device.

[0341] In an optional embodiment, the method further comprises:

[0342] Obtaining nesting information between drug packages of various specifications provided by the first medical device;

[0343] The traceability code of the drug packaging of each level of specifications of the specific to-be-used drug associated with the specific drug user is determined and returned to the third medical device.

[0344] In an optional embodiment, the method further comprises:

[0345] receiving a scanning result obtained by scanning the first traceability code on the smallest package of the retrieved medicine by a third medical device;

[0346] When it is determined that the code scanning result of the third medical device is consistent with the second traceability code allocated to the specific drug user, a verification result indicating that the drug is correctly taken is returned to the third medical device.

[0347] In an optional embodiment, the method further comprises:

[0348] Receive a drug delivery list provided by a third medical device, the drug delivery list including a second traceability code for a specific drug and information about a specific user;

[0349] Record the information of the specific drug user corresponding to the second traceability code;

[0350] Reduce the inventory of unused drugs under the third medical equipment;

[0351] The second traceability code is encoded into an intermediate code and provided to the second medical device so that the second medical device can reduce the inventory of unused drugs under the third medical device.

[0352] In an optional embodiment, the method further comprises:

[0353] Receive and save clinical case records reported by third-party medical equipment according to the second traceability code corresponding to the specific drug user.

[0354] In an optional embodiment, the method further comprises:

[0355] Receive a drug recall / destruction request from a third medical device, the drug recall / destruction request including a target traceability code;

[0356] Sending a drug recall / destruction notice to the first medical device, the drug recall / destruction notice including the target traceability code;

[0357] After the first medical device returns the completion notification, the target traceability code is marked as recycled / destroyed;

[0358] The target traceability code is encoded into an intermediate code and provided to the second medical device so that the second medical device can reduce the inventory of unused drugs under the third medical device.

[0359] In an optional embodiment, the method further comprises:

[0360] Receive a drug tracing request, which includes a target tracing code;

[0361] Extract the record data corresponding to the target traceability code from the local machine to respond to the drug traceability request.

[0362] In an optional embodiment, the method further comprises:

[0363] Receiving monitoring data provided by a monitoring device, where the monitoring data is generated by the monitoring device monitoring manual operations during the generation of index information;

[0364] Determine the submission time of the index information; extract monitoring fragments that meet the preset conditions from the monitoring data, and associate the extracted monitoring fragments with the index information.

[0365] It is worth noting that the technical details of each embodiment of the above data processing method can be referred to the aforementioned Figure 1 and Figure 4 The relevant description of the data processing system provided is too long to be repeated here, but this should not cause any loss to the scope of protection of this application.

[0366] In one possible design, Figure 5a The method shown can be implemented by a data processing device, referring to Figure 5b , the data processing device may include:

[0367] A first interactive module 50 is configured to obtain index information of the drug to be used from the first medical device, wherein the index information includes a first traceability code of the drug to be used;

[0368] The second interaction module 51 is configured to obtain mapping information between the to-be-used drug and the user from the second medical device;

[0369] The processing module 52 is configured to determine a second traceability code of a specific to-be-used drug associated with a specific drug user based on the mapping information and the index information.

[0370] Figure 5b The data processing device shown can also be used to perform Figure 5a The operations in other related embodiments of the method shown are not described here in detail to save space, but this should not cause loss of protection scope for the data processing device. Figure 5a Other operations in the relevant embodiments may be implemented based on other modules, and these modules may be configured in the same device or different devices.

[0371] Figure 6a A flow chart of another data processing method provided by an exemplary embodiment of the present application is provided. Figure 6a The data processing method provided in this embodiment can be executed by a data processing device, which can be implemented as software or a combination of software and hardware. The data processing device can be integrated into the first medical device in the aforementioned embodiment. Figure 6a As shown, the method includes:

[0372] Step 600: Obtain a first traceability code for the drug to be used;

[0373] Step 601: Generate index information of the drug to be used according to the first traceability code;

[0374] Step 602: Provide the index information to the computing device, so that the computing device can determine the second traceability code of the specific to-be-used drug associated with the specific user based on the index information and the mapping information between the to-be-used drug and the user obtained from the second medical device.

[0375] In an optional embodiment, the step of generating index information of the drug to be used according to the first traceability code includes:

[0376] Determine the allocation group to which the drug to be used belongs;

[0377] Generate index information of the drugs to be used based on their first traceability codes and the allocation groups they belong to.

[0378] In an optional embodiment, the step of generating index information of the drug to be used according to the first traceability code of the drug to be used and the allocation group to which it belongs includes:

[0379] The respective groups to which the drugs to be used belong are encrypted, and index information is generated based on the first traceability code of the drugs to be used and the encrypted allocation group.

[0380] In an optional embodiment, the step of providing the index information to the computing device includes:

[0381] encrypting the index information and sending it to the computing device;

[0382] After the index information is sent to the computing device, local data related to the index information is deleted.

[0383] In an optional embodiment, the method further comprises:

[0384] Designate drug storage facilities for drugs awaiting use;

[0385] The correspondence between the drugs to be used and the drug storage devices is provided to the computing device, so that the computing device can determine the storage temperature data of each of the drugs to be used based on the storage temperature data reported by at least one drug storage device.

[0386] In an optional embodiment, the method further comprises:

[0387] Multiple query authorizers are configured for the index information, and information of the multiple query authorizers is provided to the computing device so that the computing device can query and authenticate the index information.

[0388] In an optional embodiment, the drugs to be used are in the smallest packaging unit, and the steps for obtaining the first traceability code for the drugs to be used include:

[0389] Initiate a first traceability code acquisition request to the computing device for the smallest package of the drug, so that the computing device generates a first traceability code for the smallest package of the drug;

[0390] The first traceability code of the smallest package of the medicine is downloaded from the computing device as the first traceability code of the medicine to be used.

[0391] In an optional embodiment, the method further comprises:

[0392] For other specifications of drug packaging, a second traceability code acquisition request is initiated to the computing device, so that the computing device can generate a third traceability code for each of the other specifications of drug packaging;

[0393] Download the third traceability code of other specifications of drug packaging from the computing device.

[0394] In an optional embodiment, the method further comprises:

[0395] determining a target drug to be distributed to the third medical device from among the drugs to be used;

[0396] generating a delivery note corresponding to the third medical device based on the traceability code of at least one outermost drug package of the target drug;

[0397] A target distribution management device is specified for the outbound order; and information of the outbound order and the target distribution management device is provided to the computing device.

[0398] In an optional embodiment, the method further comprises:

[0399] A transport status monitoring request is initiated to the computing device. The transport process monitoring request includes information about the outbound order, so that the computing device can return the transport status information corresponding to the outbound order. The transport status information includes transport temperature data and / or trajectory data.

[0400] In an optional embodiment, the method further comprises:

[0401] According to the preset proportional relationship between drug packaging specifications, determine the number of drug packages of each level of specifications under the maximum package of a single drug;

[0402] Generate nesting information between drug packages based on the traceability codes and physical nesting relationships of drug packages of various specifications;

[0403] The nesting information is provided to the computing device, so that the computing device stores the nesting information.

[0404] In an optional embodiment, when there are multiple second medical devices, the method further includes:

[0405] receiving drug order information provided by the computing device, where the drug order information is generated by the target second medical device corresponding to the third medical device based on incremental drug users under the name of the third medical device and sent to the computing device;

[0406] Prepare medicines for third-party medical equipment based on drug order information.

[0407] It is worth noting that the technical details of each embodiment of the above data processing method can be referred to the aforementioned Figure 1 and Figure 4 The relevant description of the data processing system provided is too long to be repeated here, but this should not cause any loss to the scope of protection of this application.

[0408] In one possible design, Figure 6a The method shown can be implemented by a data processing device, referring to Figure 6b , the data processing device may include:

[0409] The traceability code acquisition module 60 is used to obtain a first traceability code for the drug to be used;

[0410] An index information generating module 61 is used to generate index information of the drug to be used according to the first traceability code;

[0411] The interaction module 62 is used to provide the index information to the computing device, so that the computing device can determine the second traceability code of the specific to-be-used drug associated with the specific user based on the index information and the mapping information between the to-be-used drug and the user obtained from the second medical device.

[0412] The index information generation module 61 and the interaction module 62 can be run in an independent code scanning and encryption device, and the code scanning and encryption device can also be configured with a code scanning module to scan and obtain the first traceability code of the drug to be used. The traceability code acquisition module 60 can be run in another device. Figure 6a Other operations in the relevant embodiments may be implemented based on other modules, and these modules may be configured in the same device or different devices.

[0413] Figure 6b The data processing device shown can also be used to perform Figure 6a The operations in other relevant embodiments of the illustrated method will not be described in detail here to save space, but this should not result in a loss of the protection scope of the data processing device.

[0414] Figure 7a A flowchart of another data processing method provided by an exemplary embodiment of the present application is provided. Figure 7a The data processing method provided in this embodiment can be executed by a data processing device, which can be implemented as software or a combination of software and hardware. The data processing device can be integrated into the second medical device in the aforementioned embodiment. Figure 7a As shown, the method includes:

[0415] Step 700: Obtaining medication user information;

[0416] Step 701: Obtain the intermediate code corresponding to the first traceability code of the drug to be used and the allocation group to which it belongs from the computing device;

[0417] Step 702: assign the intermediate code to the medication user based on the intermediate code and the allocation group to which the intermediate code belongs;

[0418] Step 703: Provide the mapping information between the intermediate code and the drug user to the computing device, so that the computing device can decode the intermediate code in the mapping information to determine the second traceability code of the specific drug to be used associated with the specific drug user.

[0419] The information of the drug user in step 700 may be information of the drug user in the name of a single third medical device, and accordingly, the drugs to be used in step 701 may be drugs to be used in the name of the third medical device.

[0420] In an optional embodiment, the method further comprises:

[0421] Generate drug order information based on the medication needs of incremental users under the name of third-party medical equipment;

[0422] The drug order information is provided to a computing device, so that the computing device sends the drug order information to a first medical device for drug preparation.

[0423] It is worth noting that the technical details of each embodiment of the above data processing method can be referred to the aforementioned Figure 1 and Figure 4 The relevant description of the data processing system provided is too long to be repeated here, but this should not cause any loss to the scope of protection of this application.

[0424] In one possible design, Figure 7a The method shown can be implemented by a data processing device, referring to Figure 7b , the data processing device may include:

[0425] An acquisition module 70 is used to acquire, from a computing device, an intermediate code corresponding to the first traceability code of the drug to be used and the allocation group to which it belongs;

[0426] The allocation module 71 is used to allocate the intermediate code to the user according to the intermediate code corresponding to the first traceability code of the drug to be used and the allocation group to which it belongs;

[0427] The sending module 72 is used to provide the mapping information between the intermediate code and the drug user to the computing device, so that the computing device can decode the intermediate code in the mapping information to determine the second traceability code of the specific drug to be used associated with the specific drug user.

[0428] Figure 7b The data processing device shown can also be used to perform Figure 7a The operations in other related embodiments of the method shown are not described here in detail to save space, but this should not cause any loss of the protection scope of the data processing device. Figure 7a Other operations in the relevant embodiments may be implemented based on other modules, and these modules may be configured in the same device or different devices.

[0429] Figure 8a A flowchart of another data processing method provided by an exemplary embodiment of the present application is provided. Figure 8a The data processing method provided in this embodiment can be executed by a data processing device, which can be implemented as software or a combination of software and hardware. The data processing device can be integrated into the third medical device in the aforementioned embodiment. Figure 8a As shown, the method includes:

[0430] Step 800: Send a medication query request to a computing device, where the medication query request includes information about a specific medication user.

[0431] Step 801: Receive a second traceability code for a specific to-be-used drug associated with a specific user, returned by a computing device, wherein the second traceability code is determined by the computing device based on a mapping relationship between the to-be-used drug and the user provided by a second medical device and the first traceability code of the to-be-used drug;

[0432] Step 802: Obtain the specific drug to be used according to the second traceability code and distribute it to the specific user.

[0433] In an optional embodiment, the step of obtaining the specific drug to be used according to the second traceability code includes:

[0434] Scan the traceability code of the smallest package of the drug obtained according to the received second traceability code, and upload the scan result to the computing device;

[0435] If a verification result indicating that the medication is correctly taken is received from the computing device, a medication delivery list is generated based on the second traceability code and the information of the specific medication user, and the medication delivery list is uploaded to the computing device.

[0436] In an optional embodiment, before initiating a subject medication query request to a computing device, the method further includes:

[0437] Scan the traceability code of at least one outermost drug package received to generate a warehouse entry form;

[0438] Provide the warehouse receipt to the computing device for receipt verification.

[0439] In an optional embodiment, the method further comprises:

[0440] During the transportation of at least one largest package of medicine, a transportation status monitoring request is initiated to a computing device. The transportation status monitoring request includes information of the delivery order, so that the computing device returns transportation status information corresponding to the delivery order. The transportation status information includes transportation temperature data and / or trajectory data.

[0441] When the transportation status information meets the preset requirements, the operation of generating the outbound delivery note is executed.

[0442] In an optional embodiment, the method further comprises:

[0443] Generate a clinical case record corresponding to a specific drug user, and associate the clinical case record with a second traceability code corresponding to the specific drug user;

[0444] Upload clinical case records to the computing device according to the second traceability code corresponding to the specific drug user.

[0445] In an optional embodiment, the method further comprises:

[0446] A drug recovery / destruction request is initiated to the computing device. The drug recovery / destruction request includes a target traceability code, so that the computing device can recover / destroy the unused drugs corresponding to the target traceability code.

[0447] It is worth noting that the technical details of each embodiment of the above data processing method can be referred to the aforementioned Figure 1 and Figure 4 The relevant description of the data processing system provided is too long to be repeated here, but this should not cause any loss to the scope of protection of this application.

[0448] In one possible design, Figure 8a The method shown can be implemented by a data processing device, referring to Figure 8b , the data processing device may include:

[0449] A request module 80 is configured to send a medication query request to a computing device, wherein the medication query request includes information of a specific medication user;

[0450] an acquisition module 81 configured to receive a second traceability code for a specific to-be-used drug associated with a specific user, returned by a computing device, wherein the second traceability code is determined by the computing device based on a mapping relationship between the to-be-used drug and the user provided by a second medical device and the first traceability code of the to-be-used drug;

[0451] The drug issuing module 82 is used to obtain specific drugs to be used according to the second traceability code and issue them to specific users.

[0452] Figure 8b The data processing device shown can also be used to perform Figure 8a The operations in other related embodiments of the method shown are not described here in detail to save space, but this should not cause any loss of the protection scope of the data processing device. Figure 8a Other operations in the relevant embodiments may be implemented based on other modules, and these modules may be configured in the same device or different devices.

[0453] It should be noted that the execution entity of each step of the method provided in the above embodiment can be the same device, or the method can be executed by different devices. For example, the execution entity of steps 700 to 703 can be device A; for another example, the execution entity of steps 700 and 702 can be device A, and the execution entity of step 703 can be device B; and so on.

[0454] In addition, some of the processes described in the above embodiments and the accompanying drawings include multiple operations that appear in a specific order, but it should be clearly understood that these operations may not be executed in the order in which they appear in this article or may be executed in parallel. The operation serial numbers, such as 701, 702, etc., are only used to distinguish between different operations, and the serial numbers themselves do not represent any execution order. In addition, these processes may include more or fewer operations, and these operations may be executed in sequence or in parallel. It should be noted that the descriptions of "first", "second", etc. in this article are used to distinguish different traceability codes, devices, modules, etc., and do not represent the order of precedence, nor do they limit "first" and "second" to be different types.

[0455] Figure 9 A schematic diagram of a computing device provided by an exemplary embodiment of the present application is provided. Figure 9 The computing device includes: a memory 90, a processor 91 and a communication component 92.

[0456] The processor 91 is coupled to the memory 90 and the communication component 92 and is configured to execute a computer program in the memory to:

[0457] Obtaining index information of the drug to be used from the first medical device via the communication component 92 , wherein the index information includes a first traceability code of the drug to be used;

[0458] Acquiring mapping information between the to-be-used drug and the user from the second medical device via the communication component 92;

[0459] According to the mapping information and the index information, a second traceability code of the specific to-be-used drug associated with the specific drug user is determined.

[0460] In an optional embodiment, when determining the second traceability code of a specific to-be-used drug associated with a specific drug user based on the mapping information and the index information, the processor 91 is configured to:

[0461] encoding the first traceability code of the to-be-used drug in the index information into an intermediate code, and providing the intermediate code to the second medical device so that the second medical device can assign the intermediate code to the drug user;

[0462] Obtaining mapping information between the intermediate code provided by the second medical device and the medication user;

[0463] According to the mapping information, the specific intermediate code corresponding to the specific drug user is determined, and the specific intermediate code is decoded to obtain a second traceability code.

[0464] In an optional embodiment, the index information includes the first traceability code of the drug to be used and the distribution group to which it belongs. The processor 91 is further configured to:

[0465] The allocation group to which the drug to be used belongs is provided to the second medical device, so that the second medical device generates mapping information between the intermediate code and the user according to the intermediate code corresponding to the drug to be used and the allocation group to which it belongs.

[0466] In an optional embodiment, the index information includes the first traceability code of the to-be-used drug and the distribution group to which it belongs. When the processor 91 determines the second traceability code of the specific to-be-used drug associated with the specific user based on the mapping information and the index information, it is configured to:

[0467] obtaining mapping information between medication users and allocation groups provided by a second medical device;

[0468] Based on the index information and the mapping information between the medication users and the allocation groups, a second traceability code is selected from a plurality of first traceability codes under the allocation group associated with the specific medication user.

[0469] In an optional embodiment, the index information is used as blind information in a clinical trial, and the allocation group includes an experimental group or a control group.

[0470] In an optional embodiment, the processor 91 is further configured to:

[0471] Receiving the first medical device to designate a drug storage device for drugs to be used;

[0472] receiving storage temperature data reported by at least one drug storage device;

[0473] According to the storage temperature data reported by at least one medicine storage device, the storage temperature data corresponding to each of the medicines to be used is determined.

[0474] In an optional embodiment, the processor 91 is further configured to:

[0475] Upon receiving a query request for the index information, issuing a query authentication to the plurality of query authorizers based on information of the plurality of query authorizers associated with the index information by the first medical device;

[0476] When the query authentication information returned by multiple query authorizers meets the preset conditions, the query operation on the index information is allowed.

[0477] In an optional embodiment, the medicines to be used are in the smallest packaging unit of the medicines, and the processor 91 is further configured to:

[0478] Receiving a first traceability code acquisition request initiated by a first medical device for a minimum package of a drug;

[0479] Generate the first traceability code for the smallest package of medicine and provide it to the first medical device.

[0480] In an optional embodiment, the processor 91 is further configured to:

[0481] receiving a second traceability code acquisition request initiated by the first medical device for drug packaging of other specifications;

[0482] A third traceability code is generated for each of the other specifications of the drug packaging and provided to the first medical device.

[0483] In an optional embodiment, the processor 91 is further configured to:

[0484] receiving a delivery order generated by the first medical device for the third medical device, the delivery order including a traceability code of at least one outermost drug package of a target drug among the drugs to be used that needs to be distributed to the third medical device;

[0485] receiving transport status information reported by the target distribution management device specified by the first medical device for the outbound delivery order, the transport status information including transport temperature data and trajectory data;

[0486] Determine the transportation status information corresponding to the outbound order based on the transportation status information reported by the target distribution management device.

[0487] In an optional embodiment, the processor 91 is further configured to:

[0488] receiving a transport process monitoring request initiated by the first medical device or the third medical device, wherein the transport process monitoring request includes information of a delivery order corresponding to the third medical device;

[0489] The transportation status information corresponding to the outbound order is used as the response result of the transportation process monitoring request.

[0490] In an optional embodiment, the processor 91 is further configured to:

[0491] receiving a delivery order generated by the first medical device for the third medical device, the delivery order including a traceability code of at least one outermost drug package of a target drug among the drugs to be used that needs to be distributed to the third medical device;

[0492] The identification information of the delivery order and the identification information of the target delivery management device specified by the first medical device for the delivery order are provided to a management system for managing multiple delivery management devices, so that the management system can determine the transportation status information corresponding to the delivery order.

[0493] In an optional embodiment, when there are multiple second medical devices, the processor 91 is further configured to:

[0494] Obtaining a warehouse entry form reported by the third medical device, the warehouse entry form including a traceability code of at least one outermost drug package received by the third medical device;

[0495] Determining, based on the nesting information between the drug packages of various specifications provided by the first medical device, a first traceability code of the smallest drug package contained in each of at least one outermost drug package;

[0496] The determined first traceability codes are encrypted and sent to the target second medical device corresponding to the third medical device, so that the target second medical device can distribute the minimum packages of each drug received by the third medical device to the users under the name of the third medical device, so as to generate mapping information between the drugs to be used corresponding to the third medical device and the users.

[0497] In an optional embodiment, the processor 91 is further configured to:

[0498] receiving drug order information provided by the target second medical device, where the drug order information is generated by the target second medical device based on incremental drug demand of users under the name of the third medical device;

[0499] The drug order information is sent to the first medical device, so that the first medical device can prepare drugs according to the drug order information.

[0500] In an optional embodiment, the processor 91 is further configured to:

[0501] Receive temperature monitoring data reported by a third medical device according to a third traceability code of at least one largest package of medicine during storage of the at least one largest package of medicine.

[0502] In an optional embodiment, the processor 91 is further configured to:

[0503] receiving a medication query request sent by a third medical device, the medication query request including information of a specific medication user and identification information of the third medical device;

[0504] According to the information of the specific drug user and the identification information of the third medical device, a second traceability code of the specific drug to be used associated with the specific drug user is determined and returned to the third medical device.

[0505] In an optional embodiment, the processor 91 is further configured to:

[0506] Obtaining nesting information between drug packages of various specifications provided by the first medical device;

[0507] The traceability code of the drug packaging of each level of specifications of the specific to-be-used drug associated with the specific drug user is determined and returned to the third medical device.

[0508] In an optional embodiment, the processor 91 is further configured to:

[0509] receiving a scanning result obtained by scanning the first traceability code on the smallest package of the retrieved medicine by a third medical device;

[0510] When it is determined that the code scanning result of the third medical device is consistent with the second traceability code allocated to the specific drug user, a verification result indicating that the drug is correctly taken is returned to the third medical device.

[0511] In an optional embodiment, the processor 91 is further configured to:

[0512] Receive a drug delivery list provided by a third medical device, the drug delivery list including a second traceability code for a specific drug and information about a specific user;

[0513] Record the information of the specific drug user corresponding to the second traceability code;

[0514] Reduce the inventory of unused drugs under the third medical equipment;

[0515] The second traceability code is encoded into an intermediate code and provided to the second medical device so that the second medical device can reduce the inventory of unused drugs under the third medical device.

[0516] In an optional embodiment, the processor 91 is further configured to:

[0517] Receive and save clinical case records reported by third-party medical equipment according to the second traceability code corresponding to the specific drug user.

[0518] In an optional embodiment, the processor 91 is further configured to:

[0519] Receive a drug recall / destruction request from a third medical device, the drug recall / destruction request including a target traceability code;

[0520] Sending a drug recall / destruction notice to the first medical device, the drug recall / destruction notice including the target traceability code;

[0521] After the first medical device returns the completion notification, the target traceability code is marked as recycled / destroyed;

[0522] The target traceability code is encoded into an intermediate code and provided to the second medical device so that the second medical device can reduce the inventory of unused drugs under the third medical device.

[0523] In an optional embodiment, the processor 91 is further configured to:

[0524] Receive a drug tracing request, which includes a target tracing code;

[0525] Extract the record data corresponding to the target traceability code from the local machine to respond to the drug traceability request.

[0526] In an optional embodiment, the processor 91 is further configured to:

[0527] Receiving monitoring data provided by a monitoring device, where the monitoring data is generated by the monitoring device monitoring manual operations during the generation of index information;

[0528] Determine the submission time of the index information; extract monitoring fragments that meet the preset conditions from the monitoring data, and associate the extracted monitoring fragments with the index information.

[0529] It is worth noting that the technical details of each embodiment of the above computing device can be referred to the aforementioned Figure 1 and Figure 4 The relevant description of the data processing system provided is too long to be repeated here, but this should not cause any loss to the scope of protection of this application.

[0530] Further, if Figure 9 As shown, the computing device also includes: a power supply component 93 and other components. Figure 9 Only some components are shown schematically, and it does not mean that the computing device only includes Figure 9 Components shown.

[0531] Accordingly, an embodiment of the present application further provides a computer-readable storage medium storing a computer program, which, when executed, can implement the steps that can be executed by a computing device in the above method embodiment.

[0532] Figure 10 A schematic diagram of the structure of another computing device provided by an exemplary embodiment of the present application. Figure 10 The computing device includes: a memory 100, a processor 101 and a communication component 102.

[0533] The processor 101 is coupled to the memory 100 and the communication component 102 and is configured to execute a computer program in the memory to:

[0534] Obtaining a first traceability code for the drug to be used via the communication component 102;

[0535] Generate index information of the drug to be used according to the first traceability code;

[0536] The index information is provided to the computing device through the communication component 102, so that the computing device can determine the second traceability code of the specific drug to be used associated with the specific user based on the index information and the mapping information between the drug to be used and the user obtained from the second medical device.

[0537] In an optional embodiment, when generating index information of the drug to be used according to the first traceability code, the processor 101 is configured to:

[0538] Determine the allocation group to which the drug to be used belongs;

[0539] Generate index information of the drugs to be used based on their first traceability codes and the allocation groups they belong to.

[0540] In an optional embodiment, when generating index information of the drug to be used based on the first traceability code of the drug to be used and the allocation group to which it belongs, the processor 101 is configured to:

[0541] The respective groups to which the drugs to be used belong are encrypted, and index information is generated based on the first traceability code of the drugs to be used and the encrypted allocation group.

[0542] In an optional embodiment, when providing the index information to the computing device, the processor 101 is configured to:

[0543] encrypting the index information and sending it to the computing device;

[0544] After the index information is sent to the computing device, local data related to the index information is deleted.

[0545] In an optional embodiment, the processor 101 is further configured to:

[0546] Designate drug storage facilities for drugs awaiting use;

[0547] The correspondence between the drugs to be used and the drug storage devices is provided to the computing device, so that the computing device can determine the storage temperature data of each of the drugs to be used based on the storage temperature data reported by at least one drug storage device.

[0548] In an optional embodiment, the processor 101 is further configured to:

[0549] Multiple query authorizers are configured for the index information, and information of the multiple query authorizers is provided to the computing device so that the computing device can query and authenticate the index information.

[0550] In an optional embodiment, the medicine to be used is in the smallest package of medicine as a unit. When the processor 101 obtains the first traceability code for the medicine to be used, it is used to:

[0551] Initiate a first traceability code acquisition request to the computing device for the smallest package of the drug, so that the computing device generates a first traceability code for the smallest package of the drug;

[0552] The first traceability code of the smallest package of the medicine is downloaded from the computing device as the first traceability code of the medicine to be used.

[0553] In an optional embodiment, the processor 101 is further configured to:

[0554] For other specifications of drug packaging, a second traceability code acquisition request is initiated to the computing device, so that the computing device can generate a third traceability code for each of the other specifications of drug packaging;

[0555] Download the third traceability code of other specifications of drug packaging from the computing device.

[0556] In an optional embodiment, the processor 101 is further configured to:

[0557] determining a target drug to be distributed to the third medical device from among the drugs to be used;

[0558] generating a delivery note corresponding to the third medical device based on the traceability code of at least one outermost drug package of the target drug;

[0559] A target distribution management device is specified for the outbound order; and information of the outbound order and the target distribution management device is provided to the computing device.

[0560] In an optional embodiment, the processor 101 is further configured to:

[0561] A transport status monitoring request is initiated to the computing device. The transport process monitoring request includes information about the outbound order, so that the computing device can return the transport status information corresponding to the outbound order. The transport status information includes transport temperature data and / or trajectory data.

[0562] In an optional embodiment, the processor 101 is further configured to:

[0563] According to the preset proportional relationship between drug packaging specifications, determine the number of drug packages of each level of specifications under the maximum package of a single drug;

[0564] Generate nesting information between drug packages based on the physical nesting relationship of the traceability code level of drug packages of various specifications;

[0565] The nesting information is provided to the computing device, so that the computing device stores the nesting information.

[0566] In an optional embodiment, when there are multiple second medical devices, the processor 101 is further configured to:

[0567] receiving drug order information provided by the computing device, where the drug order information is generated by the target second medical device corresponding to the third medical device based on incremental drug users under the name of the third medical device and sent to the computing device;

[0568] Prepare medicines for third-party medical equipment based on drug order information.

[0569] It is worth noting that the technical details of each embodiment of the above computing device can be referred to the aforementioned Figure 1 and Figure 4 The relevant description of the data processing system provided is too long to be repeated here, but this should not cause any loss to the scope of protection of this application.

[0570] Further, if Figure 10 As shown, the computing device further includes: a display 103, a power supply component 104 and other components. Figure 10 Only some components are shown schematically, and it does not mean that the computing device only includes Figure 10 Components shown.

[0571] Accordingly, an embodiment of the present application further provides a computer-readable storage medium storing a computer program, which, when executed, can implement the steps that can be executed by a computing device in the above method embodiment.

[0572] Figure 11 A schematic diagram of the structure of another computing device provided by an exemplary embodiment of the present application. Figure 11 The computing device includes: a memory 110 , a processor 111 and a communication component 112 .

[0573] The processor 111 is coupled to the memory 110 and the communication component 112 and is configured to execute a computer program in the memory to:

[0574] Obtaining medication user information via the communication component 112;

[0575] Obtaining the intermediate code corresponding to the first traceability code of the drug to be used and the allocation group to which it belongs from the computing device via the communication component 112;

[0576] Assign the intermediate code to the medication user based on the intermediate code and the allocation group to which the intermediate code belongs;

[0577] The mapping information between the intermediate code and the drug user is provided to the computing device through the communication component 112, so that the computing device can decode the intermediate code in the mapping information to determine the second traceability code of the specific drug to be used associated with the specific drug user.

[0578] The information of the drug user may be information of the drug user in the name of a single third medical device, and correspondingly, the drug to be used may be the drug to be used in the name of the third medical device.

[0579] In an optional embodiment, the processor 111 is further configured to:

[0580] Generate drug order information based on the medication needs of incremental users under the name of third-party medical equipment;

[0581] The drug order information is provided to a computing device, so that the computing device sends the drug order information to a first medical device for drug preparation.

[0582] It is worth noting that the technical details of each embodiment of the above computing device can be referred to the aforementioned Figure 1 and Figure 4The relevant description of the data processing system provided is too long to be repeated here, but this should not cause any loss to the scope of protection of this application.

[0583] Further, if Figure 11 As shown, the computing device also includes: a display 113, a power supply component 114 and other components. Figure 11 Only some components are shown schematically, and it does not mean that the computing device only includes Figure 11 Components shown.

[0584] Accordingly, an embodiment of the present application further provides a computer-readable storage medium storing a computer program, which, when executed, can implement the steps that can be executed by a computing device in the above method embodiment.

[0585] Figure 12 A schematic diagram of the structure of another computing device provided by an exemplary embodiment of the present application. Figure 12 The computing device includes: a memory 120, a processor 121 and a communication component 122.

[0586] The processor 121 is coupled to the memory 120 and the communication component 122, and is configured to execute a computer program in the memory to:

[0587] Sending a medication query request to a computing device via the communication component 122 , the medication query request including information of a specific medication user;

[0588] receiving, via the communication component 122, a second traceability code of a specific to-be-used drug associated with a specific drug user, returned by the computing device, wherein the second traceability code is determined by the computing device based on a mapping relationship between the to-be-used drug and the drug user provided by the second medical device and the first traceability code of the to-be-used drug;

[0589] Obtain specific drugs to be used according to the second traceability code and distribute them to specific users.

[0590] In an optional embodiment, when the processor 121 obtains the specific to-be-used drug according to the second traceability code, it is configured to:

[0591] Scan the traceability code of the smallest package of the drug obtained according to the received second traceability code, and upload the scan result to the computing device;

[0592] If a verification result indicating that the medication is correctly taken is received from the computing device, a medication delivery list is generated based on the second traceability code and the information of the specific medication user, and the medication delivery list is uploaded to the computing device.

[0593] In an optional embodiment, before initiating a subject medication query request to the computing device, the processor 121 is further configured to:

[0594] Scan the traceability code of at least one outermost drug package received to generate a warehouse entry form;

[0595] Provide the warehouse receipt to the computing device for receipt verification.

[0596] In an optional embodiment, the processor 121 is further configured to:

[0597] During the transportation of at least one largest package of medicine, a transportation status monitoring request is initiated to a computing device. The transportation status monitoring request includes information of the delivery order, so that the computing device returns transportation status information corresponding to the delivery order. The transportation status information includes transportation temperature data and / or trajectory data.

[0598] When the transportation status information meets the preset requirements, the operation of generating the outbound delivery note is executed.

[0599] In an optional embodiment, the processor 121 is further configured to:

[0600] Generate a clinical case record corresponding to a specific drug user, and associate the clinical case record with a second traceability code corresponding to the specific drug user;

[0601] Upload clinical case records to the computing device according to the second traceability code corresponding to the specific drug user.

[0602] In an optional embodiment, the processor 121 is further configured to:

[0603] A drug recovery / destruction request is initiated to the computing device. The drug recovery / destruction request includes a target traceability code, so that the computing device can recover / destroy the unused drugs corresponding to the target traceability code.

[0604] It is worth noting that the technical details of each embodiment of the above computing device can be referred to the aforementioned Figure 1 and Figure 4 The relevant description of the data processing system provided is too long to be repeated here, but this should not cause any loss to the scope of protection of this application.

[0605] Further, if Figure 12 As shown, the computing device also includes: a display 123, a power supply component 124 and other components. Figure 12 Only some components are shown schematically, and it does not mean that the computing device only includes Figure 12 Components shown.

[0606] Accordingly, an embodiment of the present application further provides a computer-readable storage medium storing a computer program, which, when executed, can implement the steps that can be executed by a computing device in the above method embodiment.

[0607] above Figure 10-12 The memory in a computer is used to store computer programs and can be configured to store various other data to support operations on the computing device. Examples of such data include instructions for any application or method operating on the computing device, contact data, phone book data, messages, pictures, videos, etc. The memory can be implemented by any type of volatile or non-volatile storage device or a combination thereof, such as static random access memory (SRAM), electrically erasable programmable read-only memory (EEPROM), erasable programmable read-only memory (EPROM), programmable read-only memory (PROM), read-only memory (ROM), magnetic memory, flash memory, magnetic disk or optical disk.

[0608] above Figure 9-12 The communication component in is configured to facilitate wired or wireless communication between the device where the communication component is located and other devices. The device where the communication component is located can access a wireless network based on a communication standard, such as WiFi, 2G, 3G, 4G / LTE, 5G and other mobile communication networks, or a combination thereof. In an exemplary embodiment, the communication component receives a broadcast signal or broadcast-related information from an external broadcast management system via a broadcast channel. In an exemplary embodiment, the communication component also includes a near field communication (NFC) module to facilitate short-range communication. For example, the NFC module can be implemented based on radio frequency identification (RFID) technology, infrared data association (IrDA) technology, ultra-wideband (UWB) technology, Bluetooth (BT) technology and other technologies.

[0609] above Figure 10-12 The display in the embodiment includes a screen, which may include a liquid crystal display (LCD) and a touch panel (TP). If the screen includes a touch panel, the screen may be implemented as a touch screen to receive input signals from a user. The touch panel includes one or more touch sensors to sense touch, slide, and gestures on the touch panel. The touch sensor may not only sense the boundary of a touch or slide action, but also detect the duration and pressure associated with the touch or slide operation.

[0610] above Figure 9-12 The power supply component in a device provides power to various components of the device in which the power supply component is located. The power supply component may include a power management system, one or more power supplies, and other components associated with generating, managing, and distributing power to the device in which the power supply component is located.

[0611] Those skilled in the art will appreciate that the embodiments of the present application can be provided as methods, systems, or computer program products. Therefore, the present application can adopt the form of a complete hardware embodiment, a complete software embodiment, or an embodiment in combination with software and hardware. Moreover, the present application can adopt the form of a computer program product implemented on one or more computer-usable storage media (including but not limited to magnetic disk storage, CD-ROM, optical storage, etc.) that contain computer-usable program code.

[0612] The present application is described with reference to the flowcharts and / or block diagrams of the methods, devices (systems), and computer program products according to the embodiments of the present application. It should be understood that each process and / or box in the flowchart and / or block diagram, as well as the combination of the processes and / or boxes in the flowchart and / or block diagram, can be implemented by computer program instructions. These computer program instructions can be provided to a processor of a general-purpose computer, a special-purpose computer, an embedded processor, or other programmable data processing device to produce a machine, so that the instructions executed by the processor of the computer or other programmable data processing device generate instructions for implementing the steps in the process. Figure 1 a process or multiple processes and / or boxes Figure 1 A device that provides the functions specified in a block or multiple blocks.

[0613] These computer program instructions may also be stored in a computer readable memory that can direct a computer or other programmable data processing device to work in a specific manner, so that the instructions stored in the computer readable memory produce an article of manufacture comprising an instruction device, which implements the process Figure 1 a process or multiple processes and / or boxes Figure 1 The function specified in one or more boxes.

[0614] These computer program instructions can also be loaded onto a computer or other programmable data processing device so that a series of operational steps are executed on the computer or other programmable device to produce a computer-implemented process, thereby providing the instructions executed on the computer or other programmable device for implementing the process. Figure 1 a process or multiple processes and / or boxes Figure 1 A step that specifies a function in one or more boxes.

[0615] In a typical configuration, a computing device includes one or more processors (CPUs), input / output interfaces, network interfaces, and memory.

[0616] Memory may include non-permanent storage in a computer-readable medium, random access memory (RAM) and / or non-volatile memory in the form of read-only memory (ROM) or flash RAM. Memory is an example of a computer-readable medium.

[0617] Computer-readable media includes permanent and non-permanent, removable and non-removable media that can be implemented by any method or technology to store information. The information can be computer-readable instructions, data structures, program modules or other data. Examples of computer storage media include, but are not limited to, phase change memory (PRAM), static random access memory (SRAM), dynamic random access memory (DRAM), other types of random access memory (RAM), read-only memory (ROM), electrically erasable programmable read-only memory (EEPROM), flash memory or other memory technology, compact disc read-only memory (CD-ROM), digital versatile disc (DVD) or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices or any other non-transmission media that can be used to store information that can be accessed by a computing device. As defined herein, computer-readable media does not include transitory computer-readable media (transitory media), such as modulated data signals and carrier waves.

[0618] It should also be noted that the terms "comprises," "includes," or any other variations thereof are intended to encompass non-exclusive inclusion, such that a process, method, commodity, or apparatus that includes a series of elements includes not only those elements but also other elements not explicitly listed, or includes elements inherent to such process, method, commodity, or apparatus. In the absence of further limitations, an element defined by the phrase "comprises a ..." does not exclude the presence of other identical elements in the process, method, commodity, or apparatus that includes the element.

[0619] The foregoing is merely an embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various changes and variations. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present application should all be included within the scope of the claims of the present application.

Claims

1. A data processing system, characterized in that: comprising a computing device, and a first medical device and a second medical device communicatively coupled to the computing device, the system further comprising a third medical device and at least one delivery management device; The first medical device is used to obtain a first traceability code for the drug to be used, generate index information of the drug to be used according to the first traceability code, and provide the index information to the computing device; determine the target drug assigned to the third medical device from the drugs to be used, and generate a delivery order corresponding to the third medical device according to the traceability code of at least one outermost drug package formed by the target drug; specify a target distribution management device for the delivery order; and provide the delivery order and information of the target distribution management device to the computing device; The second medical device is used to distribute the drug to be used to a user and provide mapping information between the drug to be used and the user to the computing device; The target delivery management device is used to report its own transportation status information to the computing device; The computing device is used to determine a second traceability code of a specific to-be-used drug associated with a specific drug user based on the mapping information and the index information; and to determine the transportation status information corresponding to the outbound delivery order corresponding to the third medical device based on the transportation status information reported by the target distribution management device.

2. The system according to claim 1, characterized in that The computing device is further used to encode the first traceability code of the to-be-used drug in the index information into an intermediate code, and provide the intermediate code to the second medical device; The second medical device is used to assign the intermediate code to a medication user and provide mapping information between the intermediate code and the medication user to the computing device; The computing device is used to determine the specific intermediate code corresponding to the specific drug user according to the mapping information, and decode the specific intermediate code to obtain the second traceability code.

3. The system according to claim 2, characterized in that The index information includes the first traceability code of the drug to be used and the distribution group to which it belongs; The computing device is used to provide the intermediate code corresponding to the drug to be used and the allocation group to which it belongs to to the second medical device; The second medical device is used to group the drug users based on the types of preset allocation groups; under each allocation group, the intermediate code under the allocation group is respectively allocated to the drug users under the allocation group to generate mapping information between the intermediate code and the drug users.

4. The system according to claim 1, characterized in that The index information includes the first traceability code of the drug to be used and the distribution group to which it belongs; The second medical device is used to assign the medication users to groups based on the preset categories of the respective groups, so as to determine mapping information between the medication users and the assigned groups, and provide the mapping information to the computing device; The computing device is used to select the second traceability code from a plurality of first traceability codes under the allocation group associated with the specific drug user based on the index information and the mapping information between the drug user and the allocation group.

5. The system according to claim 3 or 4, characterized in that: The index information serves as blind information in clinical trials, and the allocated groups include experimental groups or control groups.

6. The system according to claim 1, characterized in that The first medical device comprises a first device and a second device, wherein the first device is used to obtain a first traceability code for the drug to be used; The second device is used to scan the code of the drug to be used; generate index information of the drug to be used according to the first traceability code of the drug to be used, and provide it to the computing device.

7. The system according to claim 6, characterized in that When generating the index information of the drug to be used, the second device is used to: Determining the allocation group to which the drug to be used belongs; Index information of the drug to be used is generated according to the first traceability code of the drug to be used and the allocation group to which it belongs.

8. The system according to claim 7, characterized in that The second device is specifically used for: The respective groups to which the drugs to be used belong are encrypted, and the index information is generated based on the first traceability code of the drugs to be used and the encrypted distribution group.

9. The system according to claim 8, characterized in that The second device is used for: encrypting the index information and sending it to the computing device; After the index information is sent to the computing device, local data related to the index information is deleted.

10. The system according to claim 1, characterized in that The system further comprises a plurality of drug storage devices, wherein the plurality of drug storage devices are used to synchronize their own storage temperature data to the computing device; The first medical device is further configured to provide information of a drug storage device designated for the drug to be used to the computing device; The computing device is used to determine the storage temperature data corresponding to each of the drugs to be used based on the storage temperature data provided by the multiple drug storage devices.

11. The system according to claim 1, characterized in that The first medical device is further used to configure a plurality of query authorizers for the index information, and provide information of the plurality of query authorizers to the computing device; The computing device is also used to, upon receiving a query request for the index information, issue a query authentication to multiple query authorizers based on information of the multiple query authorizers associated with the index information, and allow query operations on the index information if the query authentication information returned by the multiple query authorizers meets preset conditions.

12. The system according to claim 1, characterized in that The medicines to be used are in the smallest packaging of medicines; The first medical device is used to initiate a first traceability code acquisition request to the computing device for the smallest package of the drug; and generate index information of the smallest package of the drug according to the first traceability code as index information of the drug to be used; The computing device is also used to generate the first traceability code for the smallest package of the drug and provide it to the first medical device.

13. The system according to claim 12, characterized in that The first medical device is further used to initiate a second traceability code acquisition request to the computing device for drug packaging of other specifications; The computing device is used to generate a third traceability code for each of the drug packages of other specifications and provide the third traceability code to the first medical device.

14. The system according to claim 13, characterized in that The first medical device is further used for: According to the preset proportional relationship between the drug packaging specifications, determine the quantity of drug packaging of each level of specifications under the maximum packaging of a single drug; Generate nesting information between drug packages based on the traceability codes and physical nesting relationships of drug packages of various specifications; The nesting information is provided to the computing device so that the computing device stores the nesting information.

15. The system according to claim 14, characterized in that The transport status information includes transport temperature data and / or trajectory data.

16. The system according to claim 15, characterized in that The first medical device and the third medical device are respectively used to initiate a transport process monitoring request to the computing device, wherein the transport process monitoring request includes identification information of the delivery order; The computing device is used to provide the transportation status information corresponding to the delivery order to the first medical device and the third medical device respectively, so as to respond to the transportation process monitoring request.

17. The system according to claim 14, characterized in that In the case where there are multiple second medical devices, the third medical device is further used to scan the traceability code of at least one outermost drug package received to generate a storage entry form; and provide the storage entry form to the computing device; The computing device is used to compare the incoming warehouse order provided by the third medical device with the outgoing warehouse order corresponding to the third medical device provided by the first medical device, and return a correct receipt notification to the third medical device if the comparison is successful; determine the first traceability code of each smallest package of the medicine received by the third medical device based on the nested information and the traceability code of at least one outermost layer of the medicine package in the incoming warehouse order; Encoding each determined first traceability code into an intermediate code and sending it to a target second medical device corresponding to the third medical device; The target second medical device is used to obtain the information of the user under the name of the third medical device, and assign the intermediate code of each smallest package of medicines received by the third medical device to the user under the name of the third medical device, so as to generate mapping information between the to-be-used medicines corresponding to the third medical device and the users.

18. The system according to claim 17, characterized in that The target second medical device is further used to generate drug order information according to the incremental drug user's drug demand when a drug user under the name of the third medical device changes; sending the drug order information to the computing device; The computing device is used to send the drug order information provided by the target second medical device to the first medical device, so that the first medical device processes the drug order information.

19. The system according to claim 1, characterized in that The third medical device is further used to send a medication query request to the computing device, wherein the medication query request includes information of the specific medication user and identification information of the third medical device; The computing device is used to determine a second traceability code of a specific to-be-used drug associated with a specific drug user according to the information of the specific drug user and the identification information of a third medical device, and return the code to the third medical device.

20. The system according to claim 19, characterized in that The computing device is also used to: The traceability codes of the drug packages of various levels of specifications to which the specific drug to be used associated with the specific drug user belongs are determined and returned to the third medical device.

21. The system according to claim 20, characterized in that The third medical device is further used to: scan the first traceability code on the smallest package of the medicine obtained, and upload the scanning result to the computing device; The computing device is also used to return a verification result of correct medication collection to the third medical device when it is determined that the code scanning result of the third medical device is consistent with the second traceability code allocated to the specific medication user.

22. The system according to claim 1, characterized in that The third medical device is further used to generate a drug delivery list after delivering the specific to-be-used drug associated with the specific drug user, wherein the drug delivery list includes the second traceability code of the specific drug and the information of the specific drug user; Uploading the drug distribution list to the computing device; The computing device is further used to record information of a specific drug user corresponding to the second traceability code; and reducing the inventory of unused drugs under the third medical device; encoding the second traceability code into an intermediate code and providing it to the second medical device so that the second medical device can reduce the inventory of unused drugs under the third medical device.

23. The system according to claim 22, characterized in that The third medical device is further used for: Generate a clinical case record corresponding to the specific drug user, and associate the clinical case record with the second traceability code corresponding to the specific drug user; The clinical case record is uploaded to the computing device according to the second traceability code corresponding to the specific drug user.

24. The system according to claim 1, characterized in that The third medical device is further used for: Initiating a drug recovery / destruction request to the computing device, wherein the drug recovery / destruction request includes a target traceability code; The computing device is further configured to send a drug recovery / destruction notification to the first medical device according to the drug recovery / destruction request, wherein the drug recovery / destruction notification includes the target traceability code; after the first medical device returns a completion notification, the target traceability code is marked as recovered / destroyed; The target traceability code is encoded into an intermediate code and provided to the second medical device so that the second medical device can reduce the inventory of unused drugs under the third medical device.

25. The system according to claim 1, characterized in that The computing device is also used to: receiving a drug tracing request, wherein the drug tracing request includes a target tracing code; The record data corresponding to the target traceability code is extracted locally to respond to the drug traceability request.

26. The system according to claim 1, characterized in that The system further includes a monitoring device; the monitoring device is used to: monitor manual operations during the generation of the index information, generate monitoring data, and synchronize the monitoring data to the computing device; The computing device is used to determine the submission time of the index information; A monitoring segment that meets a preset condition is extracted from the monitoring data, and the extracted monitoring segment is associated with the index information.

27. A data processing method, characterized in that: include: Acquire index information of the drug to be used from the first medical device, wherein the index information includes a first traceability code of the drug to be used; Acquire mapping information between the to-be-used drug and the user from a second medical device; Determining a second traceability code of a specific to-be-used drug associated with a specific drug user according to the mapping information and the index information; receiving a delivery note generated by the first medical device for a third medical device, wherein the delivery note includes a traceability code of at least one outermost drug package of a target drug among the drugs to be used that needs to be allocated to the third medical device; receiving the transport status information reported by the first medical device to the target delivery management device specified by the delivery order; The transportation status information corresponding to the delivery order is determined according to the transportation status information reported by the target distribution management device.

28. The method according to claim 27, characterized in that The step of determining the second traceability code of the specific to-be-used drug associated with the specific drug user according to the mapping information and the index information includes: encoding the first traceability code of the to-be-used drug in the index information into an intermediate code, and providing the intermediate code to the second medical device so that the second medical device can assign the intermediate code to the drug user; Acquire mapping information between the intermediate code and the medication user provided by the second medical device; According to the mapping information, the specific intermediate code corresponding to the specific drug user is determined, and the specific intermediate code is decoded to obtain the second traceability code.

29. The method according to claim 28, characterized in that The index information includes the first traceability code of the drug to be used and the distribution group to which it belongs. The method further includes: The allocation group to which the drug to be used belongs is provided to the second medical device, so that the second medical device generates mapping information between the intermediate code and the user according to the intermediate code corresponding to the drug to be used and the allocation group to which it belongs.

30. The method according to claim 27, characterized in that The index information includes the first traceability code of the to-be-used drug and the distribution group to which it belongs, and the second traceability code of the specific to-be-used drug associated with the specific drug user is determined according to the mapping information and the index information, including: Acquiring mapping information between medication users and allocation groups provided by the second medical device; Based on the index information and the mapping information between the medication users and the allocation groups, the second traceability code is selected from a plurality of first traceability codes under the allocation group associated with the specific medication user.

31. The method according to claim 29 or 30, characterized in that The index information serves as blind information in clinical trials, and the allocated groups include experimental groups or control groups.

32. The method according to claim 27, characterized in that Also includes: receiving the first medical device designating a drug storage device for the drug to be used; Receiving storage temperature data reported by at least one drug storage device; According to the storage temperature data reported by the at least one medicine storage device, the storage temperature data corresponding to each of the medicines to be used is determined.

33. The method according to claim 27, characterized in that The method further comprises: In case of receiving a query request for the index information, issuing a query authentication to the multiple query authorizers based on the information of the multiple query authorizers associated with the index information by the first medical device; In the case where the query authentication information returned by the multiple query authorizers meets a preset condition, a query operation on the index information is allowed.

34. The method according to claim 27, characterized in that The medicine to be used is in the smallest packaging unit of the medicine, and the method further comprises: Receiving a first traceability code acquisition request initiated by the first medical device for the minimum package of the drug; The first traceability code is generated for the smallest package of the drug and provided to the first medical device.

35. The method according to claim 34, characterized in that The method further comprises: Receiving a second traceability code acquisition request initiated by the first medical device for drug packaging of other specifications; A third traceability code is generated for each of the drug packages of other specifications and provided to the first medical device.

36. The method according to claim 35, characterized in that The transportation status information includes transportation temperature data and trajectory data.

37. The method according to claim 27, characterized in that The method further comprises: receiving a transport process monitoring request initiated by the first medical device or the third medical device, wherein the transport process monitoring request includes information of a delivery note corresponding to the third medical device; The transportation status information corresponding to the delivery order is used as the response result of the transportation process monitoring request.

38. The method according to claim 34, characterized in that In the case where there are multiple second medical devices, the method further includes: Obtaining a warehouse entry form reported by the third medical device, wherein the warehouse entry form includes a traceability code of at least one outermost drug package received by the third medical device; Determining, based on the nesting information between drug packages of various specifications provided by the first medical device, a first traceability code of the smallest drug package contained in each of the at least one outermost drug package; The determined first traceability codes are encoded as intermediate codes and sent to the target second medical device corresponding to the third medical device, so that the target second medical device can assign the intermediate codes of the smallest packages of each drug received by the third medical device to the users under the name of the third medical device, so as to generate mapping information between the drugs to be used corresponding to the third medical device and the users.

39. The method according to claim 38, characterized in that The method further comprises: receiving drug order information provided by the target second medical device, wherein the drug order information is generated by the target second medical device according to the incremental drug demand of drug users under the name of the third medical device; The drug order information is sent to the first medical device, so that the first medical device prepares drugs according to the drug order information.

40. The method according to claim 39, characterized in that The method further comprises: Receive temperature monitoring data reported by the third medical device according to the third traceability code of the at least one largest package of medicine during the storage process of the at least one largest package of medicine.

41. The method according to claim 27, characterized in that Also includes: receiving a medication query request sent by the third medical device, wherein the medication query request includes information of the specific medication user and identification information of the third medical device; According to the information of the specific drug user and the identification information of the third medical device, a second traceability code of the specific drug to be used associated with the specific drug user is determined and returned to the third medical device.

42. The method according to claim 27, characterized in that Also includes: Acquire nesting information between drug packages of various specifications provided by the first medical device; The traceability codes of the drug packages of various levels of specifications to which the specific drug to be used associated with the specific drug user belongs are determined and returned to the third medical device.

43. The method according to claim 42, characterized in that Also includes: receiving a scanning result obtained by the third medical device scanning the first traceability code on the smallest package of the taken medicine; When it is determined that the code scanning result of the third medical device is consistent with the second traceability code allocated to the specific drug user, a verification result indicating that the drug collection is correct is returned to the third medical device.

44. The method according to claim 43, characterized in that Also includes: receiving a drug delivery list provided by the third medical device, wherein the drug delivery list includes a second traceability code of the specific drug and information of the specific drug user; Recording the information of the specific drug user corresponding to the second traceability code; Reduce the inventory of unused drugs under the third medical equipment; The second traceability code is encoded into an intermediate code and provided to the second medical device so that the second medical device can reduce the inventory of unused drugs under the third medical device.

45. The method according to claim 27, characterized in that Also includes: Receive and save the clinical case record reported by the third medical device according to the second traceability code corresponding to the specific drug user.

46. ​​The method according to claim 27, characterized in that Also includes: receiving a drug recovery / destruction request sent by the third medical device, wherein the drug recovery / destruction request includes a target traceability code; Sending a drug recall / destruction notice to the first medical device, wherein the drug recall / destruction notice includes the target traceability code; After the first medical device returns a completion notification, marking the target traceability code as recycled / destroyed; The target traceability code is encoded into an intermediate code and provided to the second medical device so that the second medical device can reduce the inventory of unused drugs under the third medical device.

47. The method according to claim 27, characterized in that The method further comprises: receiving a drug tracing request, wherein the drug tracing request includes a target tracing code; The record data corresponding to the target traceability code is extracted locally to respond to the drug traceability request.

48. The method according to claim 27, characterized in that The method further comprises: Receiving monitoring data provided by a monitoring device, wherein the monitoring data is generated by the monitoring device monitoring a manual operation in a process of generating the index information; Determining the submission time of the index information; A monitoring segment that meets a preset condition is extracted from the monitoring data, and the extracted monitoring segment is associated with the index information.

49. A data processing method, characterized in that: include: Obtain the first traceability code for the drugs to be used; Generating index information of the drug to be used according to the first traceability code; Providing the index information to a computing device, so that the computing device can determine a second traceability code of a specific drug to be used associated with a specific user based on the index information and mapping information between the drug to be used and the user obtained from a second medical device; determining a target drug to be assigned to a third medical device from among the drugs to be used; generating a delivery order corresponding to the third medical device according to the traceability code of at least one outermost drug package of the target drug composition; A target distribution management device is designated for the delivery order; and information of the delivery order and the target distribution management device is provided to the computing device.

50. The method according to claim 49, characterized in that The step of generating index information of the drug to be used according to the first traceability code includes: Determining the allocation group to which the drug to be used belongs; Index information of the drug to be used is generated according to the first traceability code of the drug to be used and the allocation group to which it belongs.

51. The method according to claim 50, characterized in that The step of generating index information of the drug to be used according to the first traceability code of the drug to be used and the allocation group to which the drug belongs includes: The respective groups to which the drugs to be used belong are encrypted, and the index information is generated based on the first traceability code of the drugs to be used and the encrypted distribution group.

52. The method according to claim 49, characterized in that Providing the index information to a computing device includes: encrypting the index information and sending it to the computing device; After the index information is sent to the computing device, local data related to the index information is deleted.

53. The method according to claim 49, characterized in that Also includes: Designating drug storage equipment for the drugs to be used; The correspondence between the drugs to be used and the drug storage devices is provided to the computing device, so that the computing device can determine the storage temperature data of each of the drugs to be used according to the storage temperature data reported by the at least one drug storage device.

54. The method according to claim 49, characterized in that Also includes: A plurality of query authorizers are configured for the index information, and information of the plurality of query authorizers is provided to the computing device so that the computing device can query and authenticate the index information.

55. The method according to claim 49, characterized in that The drugs to be used are in the smallest packaging of drugs as a unit, and obtaining the first traceability code for the drugs to be used includes: Initiating a first traceability code acquisition request to the computing device for the minimum package of the drug, so that the computing device generates the first traceability code for the minimum package of the drug; The first traceability code of the smallest package of the medicine is downloaded from the computing device as the first traceability code of the medicine to be used.

56. The method according to claim 55, characterized in that Also includes: For drug packages of other specifications, a second traceability code acquisition request is initiated to the computing device, so that the computing device can generate a third traceability code for each of the drug packages of other specifications; The third traceability code of the drug packaging of other specifications is downloaded from the computing device.

57. The method according to claim 49, characterized in that The method further comprises: A transport status monitoring request is initiated to the computing device, wherein the transport process monitoring request includes information of the delivery order, so that the computing device returns the transport status information corresponding to the delivery order, wherein the transport status information includes transport temperature data and / or trajectory data.

58. The method according to claim 56, characterized in that Also includes: According to the preset proportional relationship between the drug packaging specifications, determine the quantity of drug packaging of each level of specifications under the maximum packaging of a single drug; Generate nesting information between drug packages based on the physical nesting relationship of the traceability code level of drug packages of various specifications; The nesting information is provided to the computing device so that the computing device stores the nesting information.

59. The method according to claim 49, characterized in that When there are multiple second medical devices, the method further includes: receiving drug order information provided by the computing device, wherein the drug order information is generated by the target second medical device corresponding to the third medical device according to the incremental drug users under the name of the third medical device and sent to the computing device; According to the drug order information, drugs are prepared for the third medical device.

60. A data processing method, characterized in that: include: Obtain information about medication users; Obtaining from the computing device the intermediate code corresponding to the first traceability code of the drug to be used and the distribution group to which it belongs; assigning the intermediate code to a medication user according to the intermediate code and the assignment group to which the intermediate code belongs; Providing mapping information between the intermediate code and the drug user to the computing device, so that the computing device decodes the intermediate code in the mapping information to determine a second traceability code of a specific drug to be used associated with a specific drug user; Generate drug order information based on the drug demand of incremental drug users under the name of the third medical device; providing the drug order information to the computing device, so that the computing device sends the drug order information to the first medical device for drug preparation; Among them, during the drug preparation process, the first medical device determines the target drug to be allocated to the third medical device from the drugs to be used, and generates a delivery note corresponding to the third medical device based on the traceability code of at least one outermost drug package formed by the target drug; specifies a target distribution management device for the delivery note; and provides information of the delivery note and the target distribution management device to the computing device.

61. A computing device, characterized in that Includes memory, processor, and communication components; The memory is used to store one or more computer instructions; The processor is coupled to the memory and the communication component and is configured to execute the one or more computer instructions for: Acquiring index information of the drug to be used from the first medical device through the communication component, wherein the index information includes a first traceability code of the drug to be used; Acquiring mapping information between the to-be-used drug and the user from a second medical device through the communication component; Determining a second traceability code of a specific to-be-used drug associated with a specific drug user according to the mapping information and the index information; receiving a delivery note generated by the first medical device for a third medical device, wherein the delivery note includes a traceability code of at least one outermost drug package of a target drug among the drugs to be used that needs to be allocated to the third medical device; receiving the transport status information reported by the first medical device to the target delivery management device specified by the delivery order; The transportation status information corresponding to the delivery order is determined according to the transportation status information reported by the target distribution management device.

62. A data processing device, characterized in that: include: A first interaction module, configured to obtain index information of the drug to be used from a first medical device, wherein the index information includes a first traceability code of the drug to be used; receiving a delivery note generated by the first medical device for a third medical device, wherein the delivery note includes a traceability code of at least one outermost drug package of a target drug among the drugs to be used that needs to be allocated to the third medical device; A second interaction module is used to obtain mapping information between the to-be-used drug and the user from a second medical device; receiving the transport status information reported by the first medical device to the target delivery management device specified by the delivery order; A processing module is used to determine the second traceability code of the specific to-be-used drug associated with the specific drug user according to the mapping information and the index information; and to determine the transportation status information corresponding to the outbound order according to the transportation status information reported by the target distribution management device.

63. A computing device, characterized in that Includes memory, processor, and communication components; The memory is used to store one or more computer instructions; The processor is coupled to the memory and the communication component and is configured to execute the one or more computer instructions for: Scan the code to obtain the first traceability code of the drugs to be used; Generating index information of the drug to be used according to the first traceability code; Providing the index information to a computing device through the communication component, so that the computing device determines a second traceability code of a specific drug to be used associated with a specific user according to the index information and mapping information between the drug to be used and the user obtained from the second medical device; determining a target drug to be assigned to a third medical device from among the drugs to be used; generating a delivery order corresponding to the third medical device according to the traceability code of at least one outermost drug package of the target drug composition; A target distribution management device is designated for the delivery order; and information of the delivery order and the target distribution management device is provided to the computing device.

64. A data processing device, characterized in that: include: A code scanning module, used to scan the code to obtain the first traceability code of the drug to be used; An index information generating module, used to generate index information of the drug to be used according to the first traceability code; An interaction module, configured to provide the index information to a computing device, so that the computing device can determine a second traceability code of a specific drug to be used associated with a specific user according to the index information and mapping information between the drug to be used and the user obtained from a second medical device; Determine a target drug to be assigned to a third medical device from the drugs to be used; generate a delivery note corresponding to the third medical device based on a traceability code of at least one outermost drug package consisting of the target drug; specify a target distribution management device for the delivery note; and provide information of the delivery note and the target distribution management device to the computing device.

65. A computing device, characterized in that Includes memory, processor, and communication components; The memory is used to store one or more computer instructions; The processor is coupled to the memory and the communication component and is configured to execute the one or more computer instructions for: obtaining information of the medication user through the communication component; Obtaining, through the communication component, from a computing device an intermediate code corresponding to a first traceability code of the drug to be used and a distribution group to which it belongs; According to the intermediate code corresponding to the first traceability code of the drug to be used and the allocation group to which it belongs, the intermediate code is allocated to the drug user; Providing mapping information between the intermediate code and the drug user to the computing device through the communication component, so that the computing device decodes the intermediate code in the mapping information to determine a second traceability code of a specific drug to be used associated with a specific drug user; Generate drug order information based on the drug demand of incremental drug users under the name of the third medical device; providing the drug order information to the computing device, so that the computing device sends the drug order information to the first medical device for drug preparation; Among them, during the drug preparation process, the first medical device determines the target drug to be allocated to the third medical device from the drugs to be used, and generates a delivery note corresponding to the third medical device based on the traceability code of at least one outermost drug package formed by the target drug; specifies a target distribution management device for the delivery note; and provides information of the delivery note and the target distribution management device to the computing device.

66. A data processing device, characterized in that: include: An acquisition module is used to obtain information of drug users; Obtaining from the computing device the intermediate code corresponding to the first traceability code of the drug to be used and the distribution group to which it belongs; A distribution module, used for distributing the intermediate code to the drug user according to the intermediate code corresponding to the first traceability code of the drug to be used and the distribution group to which it belongs; A sending module, configured to provide mapping information between the intermediate code and the drug user to the computing device, so that the computing device decodes the intermediate code in the mapping information to determine a second traceability code of a specific drug to be used associated with a specific drug user; Generate drug order information based on the drug demand of incremental drug users under the name of the third medical device; providing the drug order information to the computing device, so that the computing device sends the drug order information to the first medical device for drug preparation; Among them, during the drug preparation process, the first medical device determines the target drug to be allocated to the third medical device from the drugs to be used, and generates a delivery note corresponding to the third medical device based on the traceability code of at least one outermost drug package formed by the target drug; specifies a target distribution management device for the delivery note; and provides information of the delivery note and the target distribution management device to the computing device.

67. A computer-readable storage medium storing computer instructions, characterized in that: When the computer instructions are executed by one or more processors, the one or more processors are caused to execute the data processing method according to any one of claims 27 to 60.

Images